0	Superiority	O
0	of	O
0	the	O
0	Triple	B-arm_description
0	Combination	B-arm_description
0	of	B-arm_description
0	Bortezomib	B-arm_description
0	-	O
0	Thalidomide	B-arm_description
0	-	O
0	Dexamethasone	B-arm_description
0	Over	O
0	the	O
0	Dual	B-arm_description
0	Combination	B-arm_description
0	of	O
0	Thalidomide	B-arm_description
0	-	O
0	Dexamethasone	B-arm_description
0	in	O
0	Patients	O
0	With	O
0	Multiple	O
0	Myeloma	O
0	Progressing	O
0	or	O
0	Relapsing	O
0	After	O
0	Autologous	O
0	Transplantation	O
0	:	O
0	The	O
0	MMVAR	O
0	/	O
0	IFM	O
0	2005	O
0	-	O
0	04	O
0	Randomized	B-study_type
0	Phase	B-study_type
0	III	B-study_type
0	Trial	B-study_type
0	From	O
0	the	O
0	Chronic	O
0	Leukemia	O
0	Working	O
0	Party	O
0	of	O
0	the	O
0	European	O
0	Group	O
0	for	O
0	Blood	O
0	and	O
0	Marrow	O
0	Transplantation	O
0	Superiority	O
0	of	O
0	the	O
0	Triple	O
0	Combination	O
0	of	O
0	Bortezomib	O
0	-	O
0	Thalidomide	O
0	-	O
0	Dexamethasone	O
0	Over	O
0	the	O
0	Dual	O
0	Combination	O
0	of	O
0	Thalidomide	O
0	-	O
0	Dexamethasone	O
0	in	O
0	Patients	O
0	With	O
0	Multiple	O
0	Myeloma	O
0	Progressing	O
0	or	O
0	Relapsing	O
0	After	O
0	Autologous	O
0	Transplantation	O
0	:	O
0	The	O
0	MMVAR	O
0	/	O
0	IFM	O
0	2005	O
0	-	O
0	04	O
0	Randomized	O
0	Phase	O
0	III	O
0	Trial	O
0	From	O
0	the	O
0	Chronic	O
0	Leukemia	O
0	Working	O
0	Party	O
0	of	O
0	the	O
0	European	O
0	Group	O
0	for	O
0	Blood	O
0	and	O
0	Marrow	O
0	Transplantation	O
0	MD	O
0	,	O
0	Hô	O
0	pital	O
0	SaintLaurentGarderet	B-authors
--------------------------------------------------------------
1	laurent.garderet@sat.aphp.fr	B-authors
1	.	O
1	SimonaIacobelli	B-authors
1	PhilippeMoreau	B-authors
1	MamounDib	B-authors
1	IngridLafon	B-authors
1	DietgerNiederwieser	B-authors
1	TamasMasszi	B-authors
1	JeanFontan	B-authors
1	MauricetteMichallet	B-authors
1	AloisGratwohl	B-authors
1	GiuseppeMilone	B-authors
1	ChantalDoyen	B-authors
1	BrigittePegourie	B-authors
1	RomanHajek	B-authors
1	PhilippeCasassus	B-authors
1	BrigitteKolb	B-authors
1	CarineChaleteix	B-authors
1	BerndHertenstein	B-authors
1	FrancescoOnida	B-authors
1	HeinzLudwig	B-authors
1	NicolasKetterer	B-authors
1	ChristianKoenecke	B-authors
1	MarleenVan	B-authors
1	Os	B-authors
1	MohamadMohty	B-authors
1	JeanLuc	B-authors
1	Harousseau	B-authors
1	Andrew	B-authors
1	Cakana	B-authors
1	Norbert	B-authors
1	Claude	B-authors
1	Gorin	B-authors
1	Theo	B-authors
1	de	B-authors
1	Witte	B-authors
1	Jean	B-authors
1	Luc	B-authors
1	Harousseau	B-authors
1	Curly	B-authors
1	Morris	B-authors
--------------------------------------------------------------
2	Superiority	O
2	of	O
2	the	O
2	Triple	B-arm_description
2	Combination	B-arm_description
2	of	B-arm_description
2	Bortezomib	B-arm_description
2	-	O
2	Thalidomide	B-arm_description
2	-	O
2	Dexamethasone	B-arm_description
2	Over	O
2	the	O
2	Dual	B-arm_description
2	Combination	B-arm_description
2	of	B-arm_description
2	Thalidomide	B-arm_description
2	-	O
2	Dexamethasone	B-arm_description
2	in	O
2	Patients	O
2	With	O
2	Multiple	O
2	Myeloma	O
2	Progressing	O
2	or	O
2	Relapsing	O
2	After	O
2	Autologous	O
2	Transplantation	O
2	:	O
2	The	O
2	MMVAR	O
2	/	O
2	IFM	O
2	2005	O
2	-	O
2	04	O
2	Randomized	B-study_type
2	Phase	I-study_type
2	III	I-study_type
2	Trial	I-study_type
2	From	O
2	the	O
2	Chronic	O
2	Leukemia	O
2	Working	O
2	Party	O
2	of	O
2	the	O
2	European	O
2	Group	O
2	for	O
2	Blood	O
2	and	O
2	Marrow	O
2	Transplantation	O
2	10.1200	O
2	/	O
2	JCO.2011.37.4918	O
--------------------------------------------------------------
3	Submitted	O
3	June	O
3	7	O
3	,	O
3	2011	O
3	;	O
3	accepted	O
3	March	O
3	1	O
3	,	O
3	2012	O
3	;	O
3	MD	O
3	,	O
3	Hô	O
3	pital	O
3	SaintLaurentGarderet	B-authors
3	laurent.garderet@sat.aphp.fr	I-authors
3	.	I-authors
3	SimonaIacobelli	I-authors
3	PhilippeMoreau	I-authors
3	MamounDib	I-authors
3	IngridLafon	I-authors
3	DietgerNiederwieser	I-authors
3	TamasMasszi	I-authors
3	JeanFontan	I-authors
3	MauricetteMichallet	I-authors
3	AloisGratwohl	I-authors
3	GiuseppeMilone	I-authors
3	ChantalDoyen	I-authors
3	BrigittePegourie	I-authors
3	RomanHajek	I-authors
3	PhilippeCasassus	I-authors
3	BrigitteKolb	I-authors
3	CarineChaleteix	I-authors
3	BerndHertenstein	I-authors
3	FrancescoOnida	I-authors
3	HeinzLudwig	I-authors
3	NicolasKetterer	I-authors
3	ChristianKoenecke	I-authors
3	MarleenVan	I-authors
3	Os	I-authors
3	MohamadMohty	I-authors
3	JeanLuc	I-authors
3	Harousseau	I-authors
3	Andrew	I-authors
3	Cakana	I-authors
3	Norbert	I-authors
3	Claude	I-authors
3	Gorin	I-authors
3	Theo	I-authors
3	de	I-authors
3	Witte	I-authors
3	Jean	I-authors
3	Luc	I-authors
3	Harousseau	I-authors
3	Curly	I-authors
3	Morris	B-authors
--------------------------------------------------------------
4	Superiority	O
4	of	O
4	the	O
4	Triple	B-arm_description
4	Combination	I-arm_description
4	of	I-arm_description
4	Bortezomib	I-arm_description
4	-	I-arm_description
4	Thalidomide	I-arm_description
4	-	I-arm_description
4	Dexamethasone	I-arm_description
4	Over	O
4	the	O
4	Dual	B-arm_description
4	Combination	I-arm_description
4	of	I-arm_description
4	Thalidomide	I-arm_description
4	-	I-arm_description
4	Dexamethasone	I-arm_description
4	in	O
4	Patients	O
4	With	O
4	Multiple	O
4	Myeloma	O
4	Progressing	O
4	or	O
4	Relapsing	O
4	After	O
4	Autologous	O
4	Transplantation	O
4	:	O
4	The	O
4	MMVAR	O
4	/	O
4	IFM	O
4	2005	O
4	-	O
4	04	O
4	Randomized	O
4	Phase	O
4	III	O
4	Trial	O
4	From	O
4	the	O
4	Chronic	O
4	Leukemia	O
4	Working	O
4	Party	O
4	of	O
4	the	O
4	European	O
4	Group	O
4	for	O
4	Blood	O
4	and	O
4	Marrow	O
4	Transplantation	O
4	MD	O
4	,	O
4	Hô	O
4	pital	O
4	SaintLaurentGarderet	B-authors
--------------------------------------------------------------
5	laurent.garderet@sat.aphp.fr	B-authors
5	.	O
5	MD	B-authors
5	,	I-authors
5	Hô	I-authors
5	pital	I-authors
5	SaintLaurentGarderet	I-authors
5	MD	I-authors
5	,	I-authors
5	Hô	I-authors
5	pital	I-authors
5	Saint	I-authors
5	Laurent	I-authors
5	Garderet	I-authors
5	laurent.garderet@sat.aphp.fr	I-authors
5	.	I-authors
5	SimonaIacobelli	I-authors
5	SimonaIacobelli	I-authors
5	Simona	I-authors
5	Iacobelli	I-authors
5	PhilippeMoreau	I-authors
5	PhilippeMoreau	I-authors
5	Philippe	I-authors
5	Moreau	I-authors
5	MamounDib	I-authors
5	MamounDib	I-authors
5	Mamoun	I-authors
5	Dib	I-authors
5	IngridLafon	I-authors
5	IngridLafon	I-authors
5	Ingrid	I-authors
5	Lafon	I-authors
5	DietgerNiederwieser	I-authors
5	DietgerNiederwieser	I-authors
5	Dietger	I-authors
5	Niederwieser	I-authors
5	TamasMasszi	I-authors
5	TamasMasszi	I-authors
5	Tamas	I-authors
5	Masszi	I-authors
5	JeanFontan	I-authors
5	JeanFontan	I-authors
5	Jean	I-authors
5	Fontan	I-authors
5	MauricetteMichallet	I-authors
5	MauricetteMichallet	I-authors
5	Mauricette	I-authors
5	Michallet	I-authors
5	AloisGratwohl	I-authors
5	AloisGratwohl	I-authors
5	Alois	I-authors
5	Gratwohl	I-authors
5	GiuseppeMilone	I-authors
5	GiuseppeMilone	I-authors
5	Giuseppe	I-authors
5	Milone	I-authors
5	ChantalDoyen	I-authors
5	ChantalDoyen	I-authors
5	Chantal	I-authors
5	Doyen	I-authors
5	BrigittePegourie	I-authors
5	BrigittePegourie	I-authors
5	Brigitte	I-authors
5	Pegourie	I-authors
5	RomanHajek	I-authors
5	RomanHajek	I-authors
5	Roman	I-authors
5	Hajek	I-authors
5	PhilippeCasassus	I-authors
5	PhilippeCasassus	I-authors
5	Philippe	I-authors
5	Casassus	I-authors
5	BrigitteKolb	I-authors
5	BrigitteKolb	I-authors
5	Brigitte	I-authors
5	Kolb	I-authors
5	CarineChaleteix	I-authors
5	CarineChaleteix	I-authors
5	Carine	I-authors
5	Chaleteix	I-authors
5	BerndHertenstein	I-authors
5	BerndHertenstein	I-authors
5	Bernd	I-authors
5	Hertenstein	I-authors
5	FrancescoOnida	I-authors
5	FrancescoOnida	I-authors
5	Francesco	I-authors
5	Onida	I-authors
5	HeinzLudwig	I-authors
5	HeinzLudwig	I-authors
5	Heinz	I-authors
5	Ludwig	I-authors
5	NicolasKetterer	I-authors
5	NicolasKetterer	I-authors
5	Nicolas	I-authors
5	Ketterer	I-authors
5	ChristianKoenecke	I-authors
5	ChristianKoenecke	I-authors
5	Christian	I-authors
5	Koenecke	I-authors
5	MarleenVan	I-authors
5	Os	I-authors
5	MarleenVan	I-authors
5	Os	I-authors
5	Marleen	I-authors
5	Van	I-authors
5	Os	I-authors
5	MohamadMohty	I-authors
5	MohamadMohty	I-authors
5	Mohamad	I-authors
5	Mohty	I-authors
5	JeanLuc	I-authors
5	Harousseau	I-authors
5	JeanLuc	I-authors
5	Harousseau	I-authors
5	Jean	I-authors
5	Luc	I-authors
5	Harousseau	I-authors
5	Andrew	I-authors
5	Cakana	I-authors
5	Norbert	I-authors
5	Claude	I-authors
5	Gorin	I-authors
--------------------------------------------------------------
6	Gösta	B-authors
6	Gahrton	I-authors
6	Theo	I-authors
6	de	I-authors
6	Witte	I-authors
6	,	I-authors
6	Curly	I-authors
6	Morris	I-authors
6	Gösta	O
6	Gahrton	O
6	Superiority	O
6	of	O
6	the	O
6	Triple	B-arm_description
6	Combination	I-arm_description
6	of	I-arm_description
6	Bortezomib	I-arm_description
6	-	I-arm_description
6	Thalidomide	I-arm_description
6	-	I-arm_description
6	Dexamethasone	I-arm_description
6	Over	O
6	the	O
6	Dual	B-arm_description
6	Combination	I-arm_description
6	of	I-arm_description
6	Thalidomide	I-arm_description
6	-	I-arm_description
6	Dexamethasone	I-arm_description
6	in	O
6	Patients	O
6	With	O
6	Multiple	O
6	Myeloma	O
6	Progressing	O
6	or	O
6	Relapsing	O
6	After	O
6	Autologous	O
6	Transplantation	O
6	:	O
6	The	O
6	MMVAR	O
6	/	O
6	IFM	O
6	2005	O
6	-	O
6	04	O
6	Randomized	B-study_type
6	Phase	I-study_type
6	III	I-study_type
6	Trial	O
6	From	O
6	the	O
6	Chronic	O
6	Leukemia	O
6	Working	O
6	Party	O
6	of	O
6	the	O
6	European	O
6	Group	O
6	for	O
6	Blood	O
6	and	O
6	Marrow	O
6	Transplantation	O
6	10.1200	O
6	/	O
6	JCO.2011.37.4918	O
6	Submitted	O
6	June	O
6	7	O
6	,	O
6	2011	O
6	;	O
6	accepted	O
6	March	O
6	1	O
6	,	O
6	2012	O
6	;	O
--------------------------------------------------------------
7	Patients	O
7	with	O
7	confirmed	O
7	MM	O
7	and	O
7	measurable	O
7	disease	O
7	were	O
7	eligible	O
7	if	O
7	they	O
7	had	O
7	progressed	O
7	or	O
7	relapsed	O
7	after	O
7	at	O
7	least	O
7	one	O
7	ASCT	O
7	and	O
7	provided	O
7	it	O
7	was	O
7	their	O
7	first	O
7	progression	O
7	or	O
7	relapse	O
7	.	O
7	Previous	O
7	allogeneic	O
7	transplantation	O
7	was	O
7	prohibited	O
7	.	O
7	A	O
7	Karnofsky	O
7	performance	O
7	status	O
7	above	O
7	50	O
7	%	O
7	,	O
7	platelets	O
7	at	O
7	or	O
7	higher	O
7	than	O
7	40,000	O
7	/	O
7	L	O
7	,	O
7	absolute	O
7	neutrophil	O
7	count	O
7	at	O
7	or	O
7	higher	O
7	than	O
7	1,000	O
7	/	O
7	L	O
7	,	O
7	and	O
7	creatinine	O
7	clearance	O
7	at	O
7	or	O
7	higher	O
7	than	O
7	30	O
7	mL	O
7	/	O
7	min	O
7	were	O
7	required	O
7	.	O
7	Exclusion	O
7	criteria	O
7	included	O
7	grade	O
7	2	O
7	or	O
7	higher	O
7	peripheral	O
7	neuropathy	O
7	.	O
7	On	O
7	retrospective	O
7	analysis	O
7	,	O
7	31	O
7	patients	O
7	did	O
7	not	O
7	meet	O
7	these	O
7	criteria	O
7	,	O
7	that	O
7	is	O
7	,	O
7	15	O
7	patients	O
7	had	O
7	neuropathy	O
7	above	O
7	grade	O
7	1	O
7	,	O
7	six	O
7	had	O
7	impaired	O
7	hematopoiesis	O
7	,	O
7	four	O
7	had	O
7	impaired	O
7	kidney	O
7	function	O
7	,	O
7	five	O
7	patients	O
7	were	O
7	in	O
7	second	O
7	relapse	O
7	,	O
7	and	O
7	one	O
7	had	O
7	nonsecretory	O
7	MM	O
7	.	O
7	These	O
7	deviations	O
7	were	O
7	evenly	O
7	distributed	O
7	in	O
7	both	O
7	arms	O
7	and	O
7	,	O
7	since	O
7	the	O
7	deviations	O
7	were	O
7	considered	O
7	minor	O
7	,	O
7	all	O
7	patients	O
7	originally	O
7	included	O
7	were	O
7	analyzed	O
7	.	O
7	Women	O
7	of	O
7	childbearing	O
7	age	O
7	had	O
7	to	O
7	use	O
7	a	O
7	method	O
7	of	O
7	birth	O
7	control	O
7	and	O
7	have	O
7	a	O
7	negative	O
7	serum	O
7	or	O
7	urine	O
7	beta	O
7	-	O
7	human	O
7	chorionic	O
7	gonadotropin	O
7	pregnancy	O
7	test	O
7	at	O
7	screening	O
7	and	O
7	throughout	O
7	the	O
7	study	O
7	.	O
7	Men	O
7	had	O
7	to	O
7	use	O
7	contraception	O
7	.	O
7	Review	O
7	boards	O
7	at	O
7	participating	O
7	institutions	O
7	and	O
7	regulatory	O
7	authorities	O
7	approved	O
7	the	O
7	study	O
7	,	O
7	which	O
7	was	O
7	conducted	O
7	according	O
7	to	O
7	the	O
7	Declaration	O
7	of	O
7	Helsinki	O
7	and	O
7	International	O
7	Conference	O
7	on	O
7	Harmonisation	O
7	Good	O
7	Clinical	O
7	Practice	O
7	Guidelines	O
7	.	O
7	All	O
7	patients	O
7	provided	O
7	written	O
7	informed	O
7	consent	O
7	.	O
--------------------------------------------------------------
8	This	O
8	international	O
8	randomized	B-study_type
8	,	I-study_type
8	controlled	I-study_type
8	,	I-study_type
8	open	I-study_type
8	-	I-study_type
8	label	I-study_type
8	study	B-study_type
8	enrolled	O
8	269	O
8	patients	O
8	from	O
8	60	O
8	centers	O
8	and	O
8	randomly	O
8	assigned	O
8	them	O
8	to	O
8	the	O
8	triple	B-arm_description
8	combination	B-arm_description
8	VTD	B-arm_description
8	or	O
8	to	O
8	the	O
8	dual	B-arm_description
8	combination	I-arm_description
8	TD	I-arm_description
8	(	O
8	CONSORT	O
8	diagram	O
8	;	O
8	Fig	O
8	1	O
8	)	O
8	.	O
8	Patients	O
8	were	O
8	stratified	O
8	by	O
8	number	O
8	of	O
8	previous	O
8	ASCTs	O
8	and	O
8	by	O
8	center	O
8	at	O
8	screening	O
8	.	O
8	All	O
8	patients	O
8	received	O
8	thalidomide	B-arm_dosage
8	scheduled	I-arm_dosage
8	at	I-arm_dosage
8	200	I-arm_dosage
8	mg	I-arm_dosage
8	per	I-arm_dosage
8	day	I-arm_dosage
8	orally	I-arm_dosage
8	for	I-arm_dosage
8	1	I-arm_dosage
8	year	I-arm_dosage
8	and	I-arm_dosage
8	dexamethasone	I-arm_dosage
8	40	I-arm_dosage
8	mg	I-arm_dosage
8	per	I-arm_dosage
8	day	I-arm_dosage
8	orally	I-arm_dosage
8	for	I-arm_dosage
8	four	I-arm_dosage
8	days	I-arm_dosage
8	every	I-arm_dosage
8	3	I-arm_dosage
8	weeks	I-arm_dosage
8	for	I-arm_dosage
8	1	I-arm_dosage
8	year	I-arm_dosage
8	.	O
8	Patients	O
8	assigned	O
8	to	O
8	VTD	O
8	received	O
8	1.3	B-arm_dosage
8	mg	B-arm_dosage
8	/	B-arm_dosage
8	m	B-arm_dosage
8	2	B-arm_dosage
8	bortezomib	B-arm_dosage
8	as	B-arm_dosage
8	an	B-arm_dosage
8	intravenous	B-arm_dosage
8	bolus	B-arm_dosage
8	on	B-arm_dosage
8	days	B-arm_dosage
8	1	B-arm_dosage
8	,	B-arm_dosage
8	4	B-arm_dosage
8	,	B-arm_dosage
8	8	B-arm_dosage
8	,	O
8	and	B-arm_dosage
8	11	B-arm_dosage
8	followed	B-arm_dosage
8	by	B-arm_dosage
8	a	B-arm_dosage
8	10-day	I-arm_dosage
8	rest	I-arm_dosage
8	period	I-arm_dosage
8	(	I-arm_dosage
8	day	I-arm_dosage
8	12	I-arm_dosage
8	to	I-arm_dosage
8	day	I-arm_dosage
8	21	I-arm_dosage
8	)	I-arm_dosage
8	for	I-arm_dosage
8	eight	I-arm_dosage
8	cycles	I-arm_dosage
8	(	I-arm_dosage
8	6	I-arm_dosage
8	months	I-arm_dosage
8	)	I-arm_dosage
8	and	I-arm_dosage
8	then	I-arm_dosage
8	on	I-arm_dosage
8	days	I-arm_dosage
8	1	I-arm_dosage
8	,	I-arm_dosage
8	8	I-arm_dosage
8	,	I-arm_dosage
8	15	I-arm_dosage
8	,	I-arm_dosage
8	and	I-arm_dosage
8	22	I-arm_dosage
8	followed	I-arm_dosage
8	by	I-arm_dosage
8	a	I-arm_dosage
8	20-day	I-arm_dosage
8	rest	I-arm_dosage
8	period	I-arm_dosage
8	(	I-arm_dosage
8	day	I-arm_dosage
8	23	I-arm_dosage
8	to	I-arm_dosage
8	day	I-arm_dosage
8	42	I-arm_dosage
8	)	I-arm_dosage
8	for	I-arm_dosage
8	four	I-arm_dosage
8	cycles	I-arm_dosage
8	(	I-arm_dosage
8	6	I-arm_dosage
8	months	I-arm_dosage
8	)	I-arm_dosage
8	.	I-arm_dosage
8	Antithrombotic	O
8	prophylaxis	O
8	was	O
8	mandatory	O
8	in	O
8	both	O
8	arms	O
8	.	O
8	Enoxaparin	O
8	(	O
8	40	O
8	mg	O
8	per	O
8	day	O
8	subcutaneously	O
8	)	O
8	was	O
8	used	O
8	for	O
8	primary	O
8	prophylaxis	O
8	,	O
8	and	O
8	warfarin	O
8	was	O
8	used	O
8	for	O
8	secondary	O
8	prophylaxis	O
8	.	O
8	Prophylaxis	O
8	against	O
8	herpes	O
8	zoster	O
8	infection	O
8	was	O
8	highly	O
8	recommended	O
8	in	O
8	the	O
8	VTD	O
8	arm	O
8	.	O
8	Transfusion	O
8	support	O
8	as	O
8	well	O
8	as	O
8	neutrophils	O
8	and	O
8	erythropoietic	O
8	growth	O
8	factors	O
8	were	O
8	allowed	O
8	.	O
8	Bisphosphonates	O
8	were	O
8	used	O
8	according	O
8	to	O
8	established	O
8	guidelines	O
8	.	O
8	Dose	O
8	reduction	O
8	strategies	O
8	were	O
8	recommended	O
8	for	O
8	significant	O
8	toxicities	O
8	.	O
--------------------------------------------------------------
9	Study	O
9	treatment	O
9	continued	O
9	for	O
9	1	O
9	year	O
9	.	O
9	Treatment	O
9	was	O
9	withheld	O
9	on	O
9	withdrawal	O
9	of	O
9	the	O
9	patient	O
9	's	O
9	consent	O
9	,	O
9	disease	O
9	progression	O
9	,	O
9	or	O
9	the	O
9	occurrence	O
9	of	O
9	any	O
9	grade	O
9	4	O
9	toxic	O
9	effects	O
9	.	O
9	Patients	O
9	who	O
9	were	O
9	still	O
9	responding	O
9	after	O
9	1	O
9	year	O
9	of	O
9	treatment	O
9	could	O
9	continue	O
9	,	O
9	provided	O
9	that	O
9	treatment	O
9	was	O
9	tolerated	O
9	.	O
9	A	O
9	new	O
9	transplantation	O
9	,	O
9	either	O
9	autologous	O
9	or	O
9	allogeneic	O
9	,	O
9	could	O
9	be	O
9	performed	O
9	only	O
9	in	O
9	patients	O
9	who	O
9	completed	O
9	the	O
9	planned	O
9	1-year	O
9	treatment	O
9	.	O
9	The	O
9	study	O
9	did	O
9	not	O
9	allow	O
9	crossover	O
9	from	O
9	the	O
9	TD	B-arm_description
9	arm	B-arm_description
9	to	O
9	the	O
9	VTD	B-arm_description
9	arm	B-arm_description
9	.	O
--------------------------------------------------------------
10	The	O
10	primary	O
10	end	O
10	point	O
10	was	O
10	TTP	B-arm_efficacy_metric
10	,	B-arm_efficacy_metric
10	defined	O
10	as	O
10	the	O
10	interval	O
10	from	O
10	random	O
10	assignment	O
10	to	O
10	disease	O
10	progression	O
10	,	O
10	and	O
10	was	O
10	assessed	O
10	on	O
10	the	O
10	intent	O
10	-	O
10	to	O
10	-	O
10	treat	O
10	(	O
10	ITT	O
10	)	O
10	population	O
10	.	O
10	Secondary	O
10	end	O
10	points	O
10	included	O
10	progression	B-arm_efficacy_metric
10	-	I-arm_efficacy_metric
10	free	I-arm_efficacy_metric
10	survival	I-arm_efficacy_metric
10	(	B-arm_efficacy_metric
10	PFS	B-arm_efficacy_metric
10	)	B-arm_efficacy_metric
10	,	O
10	defined	O
10	as	O
10	time	O
10	from	O
10	random	O
10	assignment	O
10	to	O
10	progression	O
10	or	O
10	death	O
10	from	O
10	any	O
10	cause	O
10	,	O
10	OS	O
10	,	O
10	defined	O
10	as	O
10	the	O
10	interval	O
10	from	O
10	random	O
10	assignment	O
10	to	O
10	death	O
10	from	O
10	any	O
10	cause	O
10	,	O
10	overall	O
10	response	O
10	rate	O
10	(	O
10	CR	O
10	ϩ	O
10	PR	O
10	)	O
10	,	O
10	and	O
10	safety	O
10	.	O
--------------------------------------------------------------
11	Progression	O
11	and	O
11	response	O
11	were	O
11	determined	O
11	according	O
11	to	O
11	EBMT	O
11	criteria	O
11	15	O
11	with	O
11	reference	O
11	to	O
11	investigator	O
11	-	O
11	reported	O
11	TTP	B-arm_efficacy_metric
11	or	O
11	response	O
11	reports	O
11	.	O
11	Two	O
11	additional	O
11	PR	O
11	subcategories	O
11	were	O
11	defined	O
11	.	O
11	The	O
11	nCR	O
11	category	O
11	was	O
11	a	O
11	PR	O
11	subcategory	O
11	meeting	O
11	all	O
11	CR	O
11	criteria	O
11	except	O
11	for	O
11	a	O
11	positive	O
11	immunofixation	O
11	.	O
11	The	O
11	very	O
11	good	O
11	partial	O
11	response	O
11	(	O
11	VGPR	O
11	)	O
11	subcategory	O
11	(	O
11	International	O
11	Myeloma	O
11	Working	O
11	Group	O
11	[	O
11	IMWG	O
11	]	O
11	criteria	O
11	)	O
11	was	O
11	a	O
11	PR	O
11	subcategory	O
11	attained	O
11	by	O
11	patients	O
11	who	O
11	had	O
11	had	O
11	a	O
11	90	O
11	%	O
11	or	O
11	greater	O
11	reduction	O
11	in	O
11	their	O
11	serum	O
11	M	O
11	-	O
11	component	O
11	since	O
11	diagnosis	O
11	.	O
11	All	O
11	patients	O
11	,	O
11	including	O
11	those	O
11	who	O
11	discontinued	O
11	treatment	O
11	,	O
11	were	O
11	followed	O
11	up	O
11	for	O
11	progression	O
11	every	O
11	3	O
11	weeks	O
11	for	O
11	the	O
11	first	O
11	6	O
11	months	O
11	and	O
11	every	O
11	6	O
11	weeks	O
11	thereafter	O
11	.	O
11	Safety	O
11	,	O
11	assessed	O
11	in	O
11	all	O
11	patients	O
11	who	O
11	received	O
11	one	O
11	or	O
11	more	O
11	drug	O
11	doses	O
11	until	O
11	30	O
11	days	O
11	after	O
11	the	O
11	last	O
11	dose	O
11	,	O
11	was	O
11	graded	O
11	according	O
11	to	O
11	National	O
11	Cancer	O
11	Institute	O
11	Common	O
11	Toxicity	O
11	Criteria	O
11	(	O
11	NCI	O
11	CTC	O
11	,	O
11	version	O
11	3	O
11	)	O
11	.	O
--------------------------------------------------------------
12	The	O
12	study	O
12	was	O
12	designed	O
12	to	O
12	provide	O
12	90	O
12	%	O
12	power	O
12	to	O
12	detect	O
12	a	O
12	hazard	B-arm_efficacy_metric
12	ratio	I-arm_efficacy_metric
12	(	I-arm_efficacy_metric
12	HR	I-arm_efficacy_metric
12	)	I-arm_efficacy_metric
12	of	O
12	0.67	O
12	(	B-arm_efficacy_metric
12	VTD	I-arm_efficacy_metric
12	v	I-arm_efficacy_metric
12	TD	I-arm_efficacy_metric
12	)	I-arm_efficacy_metric
12	for	I-arm_efficacy_metric
12	TTP	I-arm_efficacy_metric
12	at	O
12	a	O
12	one	O
12	-	O
12	sided	O
12	overall	O
12	significance	O
12	level	O
12	of	O
12	0.025	O
12	.	O
12	Four	O
12	interim	O
12	analyses	O
12	were	O
12	planned	O
12	to	O
12	test	O
12	for	O
12	efficacy	O
12	and	O
12	futility	O
12	using	O
12	an	O
12	alpha	O
12	-	O
12	spending	O
12	function	O
12	as	O
12	for	O
12	O'Brien	O
12	-	O
12	Fleming	O
12	-	O
12	type	O
12	boundaries	O
12	(	O
12	for	O
12	details	O
12	,	O
12	see	O
12	Fig	O
12	1	O
12	;	O
12	implementation	O
12	in	O
12	EAST	O
12	v	O
12	3.1.0	O
12	,	O
12	Cambridge	O
12	,	O
12	MA	O
12	)	O
12	.	O
12	The	O
12	trial	O
12	was	O
12	stopped	O
12	for	O
12	superiority	O
12	of	O
12	VTD	B-arm_description
12	over	O
12	TD	O
12	after	O
12	the	O
12	second	O
12	interim	O
12	analysis	O
12	performed	O
12	after	O
12	134	O
12	events	O
12	and	O
12	a	O
12	median	O
12	follow	O
12	-	O
12	up	O
12	of	O
12	24	O
12	months	O
12	.	O
--------------------------------------------------------------
13	Median	B-arm_efficacy_metric
13	TTP	I-arm_efficacy_metric
13	was	O
13	estimated	O
13	from	O
13	the	O
13	cumulative	O
13	incidence	O
13	curve	O
13	for	O
13	progression	O
13	(	O
13	death	O
13	without	O
13	progression	O
13	was	O
13	a	O
13	competing	O
13	risk	O
13	)	O
13	.	O
13	The	O
13	adjusted	O
13	analysis	O
13	was	O
13	performed	O
13	on	O
13	the	O
13	stratified	O
13	Cox	O
13	regression	O
13	for	O
13	the	O
13	cause	O
13	-	O
13	specific	O
13	hazard	O
13	.	O
13	Similar	O
13	methods	O
13	for	O
13	competing	O
13	risk	O
13	end	O
13	points	O
13	were	O
13	used	O
13	to	O
13	calculate	O
13	time	O
13	to	O
13	achievement	O
13	of	O
13	response	O
13	(	O
13	with	O
13	death	O
13	and	O
13	progression	O
13	as	O
13	competing	O
13	events	O
13	)	O
13	.	O
13	The	O
13	Kaplan	O
13	-	O
13	Meier	O
13	probability	O
13	estimator	O
13	and	O
13	Cox	O
13	models	O
13	were	O
13	used	O
13	to	O
13	calculate	O
13	PFS	B-arm_efficacy_metric
13	,	O
13	OS	O
13	,	O
13	and	O
13	duration	O
13	of	O
13	response	O
13	(	O
13	DOR	O
13	)	O
13	.	O
13	All	O
13	analyses	O
13	were	O
13	performed	O
13	using	O
13	R	O
13	v	O
13	2.10.0	O
13	software	O
13	(	O
13	http://www.r-project.org	O
13	)	O
13	.	O
--------------------------------------------------------------
14	From	O
14	January	O
14	2006	O
14	to	O
14	July	O
14	2010	O
14	,	O
14	135	O
14	and	O
14	134	O
14	patients	B-study_type
14	were	B-study_type
14	randomly	B-study_type
14	assigned	B-study_type
14	to	O
14	VTD	B-arm_description
14	and	O
14	TD	B-arm_description
14	,	O
14	respectively	O
14	(	O
14	Fig	O
14	1	O
14	)	O
14	.	O
14	Their	O
14	baseline	O
14	demographic	O
14	data	O
14	and	O
14	other	O
14	characteristics	O
14	,	O
14	including	O
14	number	O
14	of	O
14	prior	O
14	ASCTs	O
14	,	O
14	were	O
14	well	O
14	balanced	O
14	(	O
14	Table	O
14	1	O
14	)	O
14	.	O
14	Median	O
14	follow	O
14	-	O
14	up	O
14	at	O
14	the	O
14	last	O
14	update	O
14	(	O
14	March	O
14	2	O
14	,	O
14	2011	O
14	)	O
14	was	O
14	30	O
14	months	O
14	(	O
14	range	O
14	,	O
14	1	O
14	to	O
14	62	O
14	months	O
14	)	O
14	with	O
14	22	O
14	patients	O
14	still	O
14	being	O
14	treated	O
14	(	O
14	11	O
14	in	O
14	each	O
14	arm	O
14	)	O
14	.	O
--------------------------------------------------------------
15	Median	O
15	TTP	O
15	was	O
15	longer	O
15	in	O
15	patients	O
15	receiving	O
15	VTD	B-arm_description
15	than	O
15	TD	B-arm_description
15	(	O
15	19.5	O
15	v	O
15	13.8	O
15	months	O
15	)	O
15	.	O
15	VTD	O
15	reduced	O
15	the	O
15	risk	O
15	of	O
15	developing	O
15	disease	O
15	progression	O
15	by	O
15	40	O
15	%	O
15	(	O
15	HR	O
15	,	O
15	0.59	O
15	;	O
15	95	O
15	%	O
15	CI	O
15	,	O
15	0.44	O
15	to	O
15	0.80	O
15	;	O
15	P	O
15	ϭ	O
15	.001	O
15	;	O
15	Fig	O
15	2A	O
15	)	O
15	.	O
15	Median	B-arm_efficacy_metric
15	PFS	I-arm_efficacy_metric
15	was	O
15	significantly	O
15	longer	O
15	for	O
15	VTD	O
15	than	O
15	TD	O
15	(	O
15	18.3	B-arm_efficacy_results
15	months	I-arm_efficacy_results
15	[	I-arm_efficacy_results
15	95	I-arm_efficacy_results
15	%	I-arm_efficacy_results
15	CI	I-arm_efficacy_results
15	,	I-arm_efficacy_results
15	15.5	I-arm_efficacy_results
15	to	I-arm_efficacy_results
15	20.6	I-arm_efficacy_results
15	months	I-arm_efficacy_results
15	]	I-arm_efficacy_results
15	v	O
15	13.6	B-arm_efficacy_results
15	months	I-arm_efficacy_results
15	[	I-arm_efficacy_results
15	95	I-arm_efficacy_results
15	%	I-arm_efficacy_results
15	CI	I-arm_efficacy_results
15	,	I-arm_efficacy_results
15	9.9	I-arm_efficacy_results
15	to	I-arm_efficacy_results
15	16.1	I-arm_efficacy_results
15	months	I-arm_efficacy_results
15	]	I-arm_efficacy_results
15	;	I-arm_efficacy_results
15	HR	I-arm_efficacy_results
15	,	I-arm_efficacy_results
15	0.61	I-arm_efficacy_results
15	;	I-arm_efficacy_results
15	95	I-arm_efficacy_results
15	%	I-arm_efficacy_results
15	CI	I-arm_efficacy_results
15	,	I-arm_efficacy_results
15	0.45	I-arm_efficacy_results
15	to	I-arm_efficacy_results
15	0.81	I-arm_efficacy_results
15	;	I-arm_efficacy_results
15	P	I-arm_efficacy_results
15	ϭ	I-arm_efficacy_results
15	.001	I-arm_efficacy_results
15	;	I-arm_efficacy_results
15	Fig	B-arm_efficacy_results
15	2B	B-arm_efficacy_results
15	)	B-arm_efficacy_results
15	.	O
15	During	O
15	the	O
15	1-year	O
15	treatment	O
15	period	O
15	(	O
15	cutoff	O
15	,	O
15	March	O
15	2	O
15	,	O
15	2011	O
15	)	O
15	,	O
15	we	O
15	recorded	O
15	14	O
15	deaths	O
15	for	O
15	VTD	O
15	and	O
15	20	O
15	deaths	O
15	for	O
15	TD	O
15	,	O
15	11	O
15	cases	O
15	versus	O
15	17	O
15	cases	O
15	of	O
15	relapse	O
15	/	O
15	progression	O
15	,	O
15	three	O
15	cases	O
15	versus	O
15	one	O
15	case	O
15	of	O
15	infection	O
15	,	O
15	and	O
15	zero	O
15	cases	O
15	versus	O
15	two	O
15	cases	O
15	of	O
15	secondary	O
15	malignancy	O
15	.	O
15	The	O
15	24-month	O
15	OS	O
15	rates	O
15	were	O
15	not	O
15	significantly	O
15	different	O
15	(	O
15	71	O
15	%	O
15	[	O
15	95	O
15	%	O
15	CI	O
15	,	O
15	63	O
15	%	O
15	to	O
15	81	O
15	%	O
15	]	O
15	for	O
15	VTD	O
15	v	O
15	65	O
15	%	O
15	[	O
15	95	O
15	%	O
15	CI	O
15	,	O
15	57	O
15	%	O
15	to	O
15	75	O
15	%	O
15	]	O
15	for	O
15	TD	O
15	;	O
15	P	O
15	ϭ	O
15	.093	O
15	;	O
15	Fig	O
15	2C	O
15	)	O
15	.	O
15	Median	O
15	TTP	O
15	was	O
15	longer	O
15	in	O
15	patients	O
15	receiving	O
15	VTD	O
15	than	O
15	TD	O
15	regardless	O
15	of	O
15	the	O
15	number	O
15	of	O
15	previous	O
15	ASCTs	O
15	(	O
15	one	O
15	or	O
15	more	O
15	;	O
15	Fig	O
15	3	O
15	)	O
15	.	O
--------------------------------------------------------------
16	Complete	O
16	response	O
16	(	O
16	CR	O
16	ϩ	O
16	nCR	O
16	)	O
16	rate	O
16	was	O
16	higher	O
16	for	O
16	VTD	B-arm_description
16	than	O
16	for	O
16	TD	B-arm_description
16	(	O
16	45	O
16	%	O
16	v	O
16	25	O
16	%	O
16	;	O
16	P	O
16	ϭ	O
16	.001	O
16	)	O
16	,	O
16	and	O
16	the	O
16	median	O
16	DOR	O
16	was	O
16	longer	O
16	(	O
16	17.2	O
16	v	O
16	13.4	O
16	months	O
16	;	O
16	P	O
16	ϭ	O
16	.03	O
16	)	O
16	.	O
16	If	O
16	the	O
16	VGPRs	O
16	were	O
16	included	O
16	with	O
16	the	O
16	complete	O
16	responders	O
16	(	O
16	CR	O
16	ϩ	O
16	nCR	O
16	)	O
16	,	O
16	the	O
16	response	O
16	rate	O
16	rose	O
16	to	O
16	56	O
16	%	O
16	for	O
16	VTD	O
16	and	O
16	35	O
16	%	O
16	for	O
16	TD	O
16	(	O
16	P	O
16	Ͻ	O
16	.001	O
16	;	O
16	Table	O
16	2	O
16	)	O
16	.	O
16	Median	O
16	time	O
16	to	O
16	first	O
16	response	O
16	(	O
16	PR	O
16	or	O
16	better	O
16	)	O
16	was	O
16	significantly	O
16	shorter	O
16	in	O
16	patients	O
16	treated	O
16	with	O
16	VTD	O
16	than	O
16	in	O
16	those	O
16	treated	O
16	with	O
16	TD	O
16	(	O
16	1.5	O
16	v	O
16	2.6	O
16	months	O
16	;	O
16	P	O
16	Յ	O
16	.001	O
16	)	O
16	.	O
--------------------------------------------------------------
17	In	O
17	a	O
17	multivariate	O
17	analysis	O
17	of	O
17	the	O
17	overall	O
17	study	O
17	population	O
17	,	O
17	randomization	B-study_type
17	to	O
17	receive	O
17	VTD	B-arm_description
17	was	O
17	the	O
17	key	O
17	independent	O
17	variable	O
17	positively	O
17	related	O
17	to	O
17	a	O
17	better	O
17	TTP	O
17	(	O
17	HR	O
17	,	O
17	0.47	O
17	;	O
17	95	O
17	%	O
17	CI	O
17	,	O
17	0.31	O
17	to	O
17	0.72	O
17	;	O
17	P	O
17	Ͻ	O
17	.001	O
17	)	O
17	.	O
17	The	O
17	variables	O
17	related	O
17	to	O
17	a	O
17	worse	O
17	TTP	O
17	were	O
17	high	O
17	␤	O
17	2microglobulin	O
17	(	O
17	for	O
17	the	O
17	logarithm	O
17	:	O
17	HR	O
17	,	O
17	2.41	O
17	;	O
17	95	O
17	%	O
17	CI	O
17	,	O
17	1.63	O
17	to	O
17	3.58	O
17	;	O
17	P	O
17	Ͻ	O
17	.001	O
17	)	O
17	,	O
17	high	O
17	International	O
17	Staging	O
17	System	O
17	score	O
17	(	O
17	HR	O
17	,	O
17	1.53	O
17	;	O
17	95	O
17	%	O
17	CI	O
17	,	O
17	1.16	O
17	to	O
17	2.02	O
17	;	O
17	P	O
17	ϭ	O
17	.02	O
17	)	O
17	,	O
17	and	O
17	a	O
17	chromosome	O
17	13	O
17	deletion	O
17	(	O
17	HR	O
17	,	O
17	2.3	O
17	;	O
17	95	O
17	%	O
17	CI	O
17	,	O
17	1.49	O
17	to	O
17	3.57	O
17	;	O
17	P	O
17	Ͻ	O
17	.001	O
17	)	O
17	.	O
17	A	O
17	secondary	O
17	analysis	O
17	showed	O
17	that	O
17	early	O
17	relapse	O
17	,	O
17	within	O
17	1	O
17	year	O
17	from	O
17	last	O
17	ASCT	O
17	,	O
17	remained	O
17	a	O
17	bad	O
17	prognosis	O
17	parameter	O
17	,	O
17	but	O
17	this	O
17	risk	O
17	factor	O
17	had	O
17	a	O
17	lower	O
17	impact	O
17	in	O
17	the	O
17	VTD	O
17	group	O
17	.	O
--------------------------------------------------------------
18	Efficacy	O
18	and	O
18	Safety	O
18	of	O
18	Bortezomib	B-arm_description
18	plus	I-arm_description
18	Dexamethasone	I-arm_description
18	Therapy	O
18	for	O
18	Refractory	O
18	or	O
18	Relapsed	O
18	Multiple	O
18	Myeloma	O
18	:	O
18	Once	O
18	-	O
18	weekly	O
18	Administration	O
18	of	O
18	Bortezomib	O
18	may	O
18	Reduce	O
18	the	O
18	Incidence	O
18	of	O
18	Gastrointestinal	O
18	Adverse	O
18	Events	O
18	Efficacy	O
18	and	O
18	Safety	O
18	of	O
18	Bortezomib	O
18	plus	O
18	Dexamethasone	O
18	Therapy	O
18	for	O
18	Refractory	O
18	or	O
18	Relapsed	O
18	Multiple	O
18	Myeloma	O
18	:	O
18	Once	O
18	-	O
18	weekly	O
18	Administration	O
18	of	O
18	Bortezomib	O
18	may	O
18	Reduce	O
18	the	O
18	Incidence	O
18	of	O
18	Gastrointestinal	O
18	Adverse	O
18	Events	O
18	MDToshihiroFukushima	O
--------------------------------------------------------------
19	Efficacy	O
19	and	O
19	Safety	O
19	of	O
19	Bortezomib	B-arm_description
19	plus	I-arm_description
19	Dexamethasone	I-arm_description
19	Therapy	O
19	for	O
19	Refractory	O
19	or	O
19	Relapsed	O
19	Multiple	O
19	Myeloma	O
19	:	O
19	Once	O
19	-	O
19	weekly	O
19	Administration	O
19	of	O
19	Bortezomib	O
19	may	O
19	Reduce	O
19	the	O
19	Incidence	O
19	of	O
19	Gastrointestinal	O
19	Adverse	O
19	Events	O
--------------------------------------------------------------
20	Efficacy	O
20	and	O
20	Safety	O
20	of	O
20	Bortezomib	B-arm_description
20	plus	B-arm_description
20	Dexamethasone	B-arm_description
20	Therapy	O
20	for	O
20	Refractory	O
20	or	O
20	Relapsed	O
20	Multiple	O
20	Myeloma	O
20	:	O
20	Once	O
20	-	O
20	weekly	O
20	Administration	O
20	of	O
20	Bortezomib	O
20	may	O
20	Reduce	O
20	the	O
20	Incidence	O
20	of	O
20	Gastrointestinal	O
20	Adverse	O
20	Events	O
20	MDToshihiroFukushima	B-authors
--------------------------------------------------------------
21	Department	O
21	of	O
21	Hematology	O
21	and	O
21	Immunology	O
21	HisanoriUmehara	O
21	Hisanori	O
21	Umehara	O
21	Department	O
21	of	O
21	Hematology	O
21	and	O
21	Immunology	O
21	Department	O
21	of	O
21	Hematology	O
21	and	O
21	Immunology	O
21	Department	O
21	of	O
21	Hematology	O
21	and	O
21	Immunology	O
21	Kanazawa	O
21	Medical	O
21	University	O
--------------------------------------------------------------
22	Japan	O
22	1	O
22	-	O
22	1	O
22	Daigaku	O
22	920	O
22	-	O
22	0293	O
22	Uchinada	O
22	Ishikawa	O
22	Japan	O
22	Efficacy	O
22	and	O
22	Safety	O
22	of	O
22	Bortezomib	B-arm_description
22	plus	I-arm_description
22	Dexamethasone	I-arm_description
22	Therapy	O
22	for	O
22	Refractory	O
22	or	O
22	Relapsed	O
22	Multiple	O
22	Myeloma	O
22	:	O
22	Once	O
22	-	O
22	weekly	O
22	Administration	O
22	of	O
22	Bortezomib	O
22	may	O
22	Reduce	O
22	the	O
22	Incidence	O
22	of	O
22	Gastrointestinal	O
22	Adverse	O
22	Events	O
22	Received	O
22	April	O
22	6	O
22	,	O
22	2011	O
22	Revised	O
22	May	O
22	23	O
22	,	O
22	2011	O
22	Accepted	O
22	May	O
22	24	O
22	,	O
22	2011	O
--------------------------------------------------------------
23	Multiple	O
23	myeloma	O
23	(	O
23	MM	O
23	)	O
23	is	O
23	a	O
23	hematological	O
23	malignancy	O
23	characterized	O
23	by	O
23	monoclonal	O
23	proliferation	O
23	of	O
23	plasma	O
23	cells	O
23	and	O
23	the	O
23	presence	O
23	of	O
23	monoclonal	O
23	immunoglobulin	O
23	in	O
23	serum	O
23	and	O
23	urine	O
23	.	O
23	Its	O
23	common	O
23	clinical	O
23	features	O
23	are	O
23	anemia	O
23	,	O
23	renal	O
23	dysfunction	O
23	,	O
23	osteolysis	O
23	and	O
23	hypercalcemia	O
23	(	O
23	1)(2)(3	O
23	)	O
23	.	O
23	In	O
23	the	O
23	past	O
23	decade	O
23	,	O
23	there	O
23	have	O
23	been	O
23	major	O
23	advances	O
23	as	O
23	a	O
23	result	O
23	of	O
23	new	O
23	anti	O
23	-	O
23	myeloma	O
23	agents	O
23	(	O
23	2,3	O
23	)	O
23	.	O
23	A	O
23	proteasome	O
23	inhibitor	O
23	,	O
23	bortezomib	O
23	,	O
23	is	O
23	one	O
23	of	O
23	these	O
23	new	O
23	agents	O
23	(	O
23	4,5	O
23	)	O
23	and	O
23	has	O
23	been	O
23	successfully	O
23	used	O
23	for	O
23	the	O
23	treatment	O
23	of	O
23	MM	O
23	.	O
23	Bortezomib	O
23	plus	O
23	dexamethasone	O
23	(	O
23	BD	O
23	)	O
23	therapy	O
23	has	O
23	been	O
23	established	O
23	as	O
23	one	O
23	of	O
23	the	O
23	most	O
23	promising	O
23	therapies	O
23	for	O
23	refractory	O
23	or	O
23	relapsed	O
23	MM	O
23	.	O
23	On	O
23	the	O
23	other	O
23	hand	O
23	,	O
23	the	O
23	use	O
23	of	O
23	bortezomib	O
23	is	O
23	associated	O
23	with	O
23	some	O
23	severe	O
23	adverse	O
23	events	O
23	,	O
23	with	O
23	22	O
23	%	O
23	and	O
23	37	O
23	%	O
23	of	O
23	patients	O
23	being	O
23	unable	O
23	to	O
23	continue	O
23	bortezomib	O
23	therapy	O
23	due	O
23	to	O
23	adverse	O
23	events	O
23	in	O
23	the	O
23	SUMMIT	O
23	and	O
23	APEX	O
23	study	O
23	,	O
23	respectively	O
23	(	O
23	6,7	O
23	)	O
23	.	O
--------------------------------------------------------------
24	Bortezomib	O
24	-	O
24	melphalan	O
24	-	O
24	prednisolone	O
24	(	O
24	VMP	O
24	)	O
24	therapy	O
24	has	O
24	also	O
24	been	O
24	established	O
24	as	O
24	a	O
24	standard	O
24	chemotherapy	O
24	for	O
24	newly	O
24	diagnosed	O
24	MM	O
24	patients	O
24	who	O
24	were	O
24	not	O
24	eligible	O
24	for	O
24	high	O
24	-	O
24	dose	O
24	therapy	O
24	followed	O
24	by	O
24	autologous	O
24	peripheral	O
24	blood	O
24	stem	O
24	cell	O
24	transplantation	O
24	(	O
24	auto	O
24	-	O
24	PBSCT	O
24	)	O
24	;	O
24	however	O
24	,	O
24	46	O
24	%	O
24	of	O
24	patients	O
--------------------------------------------------------------
25	Patients	O
25	.	O
25	We	O
25	retrospectively	B-study_type
25	analyzed	B-study_type
25	the	B-study_type
25	medical	B-study_type
25	records	B-study_type
25	of	O
25	22	O
25	patients	O
25	with	O
25	relapsed	O
25	or	O
25	refractory	O
25	MM	O
25	who	O
25	began	O
25	BD	B-arm_description
25	therapy	O
25	in	O
25	Kanazawa	O
25	Medical	O
25	University	O
25	Hospital	O
25	between	O
25	January	O
25	2007	O
25	and	O
25	July	O
25	2010	O
25	.	O
25	The	O
25	diagnosis	O
25	of	O
25	MM	O
25	was	O
25	confirmed	O
25	using	O
25	the	O
25	International	O
25	Myeloma	O
25	Working	O
25	Group	O
25	(	O
25	IMWG	O
25	)	O
25	criteria	O
25	(	O
25	1	O
25	)	O
25	.	O
25	The	O
25	clinical	O
25	stage	O
25	was	O
25	determined	O
25	by	O
25	the	O
25	International	O
25	Staging	O
25	System	O
25	(	O
25	ISS	O
25	)	O
25	(	O
25	9	O
25	)	O
25	.	O
--------------------------------------------------------------
26	Patients	O
26	received	O
26	bortezomib	B-arm_dosage
26	(	I-arm_dosage
26	1.3	I-arm_dosage
26	mg	I-arm_dosage
26	/	I-arm_dosage
26	m	I-arm_dosage
26	2	I-arm_dosage
26	)	I-arm_dosage
26	as	I-arm_dosage
26	an	I-arm_dosage
26	intravenous	I-arm_dosage
26	bolus	I-arm_dosage
26	on	I-arm_dosage
26	days	I-arm_dosage
26	1	I-arm_dosage
26	,	I-arm_dosage
26	4	I-arm_dosage
26	,	I-arm_dosage
26	8	I-arm_dosage
26	and	I-arm_dosage
26	11	I-arm_dosage
26	in	I-arm_dosage
26	a	I-arm_dosage
26	3-week	I-arm_dosage
26	cycle	I-arm_dosage
26	(	I-arm_dosage
26	twiceweekly	I-arm_dosage
26	administration	I-arm_dosage
26	)	I-arm_dosage
26	,	I-arm_dosage
26	or	I-arm_dosage
26	on	I-arm_dosage
26	days	I-arm_dosage
26	1	I-arm_dosage
26	,	I-arm_dosage
26	8	I-arm_dosage
26	,	I-arm_dosage
26	15	I-arm_dosage
26	and	I-arm_dosage
26	22	I-arm_dosage
26	in	I-arm_dosage
26	a	I-arm_dosage
26	5-week	I-arm_dosage
26	cycle	I-arm_dosage
26	(	I-arm_dosage
26	once	I-arm_dosage
26	-	I-arm_dosage
26	weekly	I-arm_dosage
26	administration	I-arm_dosage
26	)	I-arm_dosage
26	.	O
26	Dexamethasone	B-arm_dosage
26	at	I-arm_dosage
26	20	I-arm_dosage
26	mg	I-arm_dosage
26	was	I-arm_dosage
26	given	I-arm_dosage
26	intravenously	I-arm_dosage
26	or	I-arm_dosage
26	orally	I-arm_dosage
26	on	I-arm_dosage
26	the	I-arm_dosage
26	day	I-arm_dosage
26	of	I-arm_dosage
26	and	I-arm_dosage
26	day	I-arm_dosage
26	after	I-arm_dosage
26	bortezomib	I-arm_dosage
26	treatment	I-arm_dosage
26	.	O
26	BD	O
26	therapy	O
26	was	O
26	continued	O
26	until	O
26	achieving	O
26	a	O
26	complete	O
26	response	O
26	(	O
26	CR	O
26	)	O
26	,	O
26	disease	O
26	progression	O
26	or	O
26	the	O
26	development	O
26	of	O
26	severe	O
26	adverse	O
26	events	O
26	.	O
26	If	O
26	patients	O
26	were	O
26	eligible	O
26	for	O
26	high	O
26	-	O
26	dose	O
26	therapy	O
26	,	O
26	hematopoietic	O
26	stem	O
26	cells	O
26	were	O
26	harvested	O
26	by	O
26	high	O
26	-	O
26	dose	O
26	cyclophosphamide	O
26	(	O
26	3	O
26	g	O
26	/	O
26	m	O
26	2	O
26	)	O
26	,	O
26	and	O
26	high	O
26	-	O
26	dose	O
26	melphalan	O
26	(	O
26	140	O
26	mg	O
26	/	O
26	m	O
26	2	O
26	)	O
26	was	O
26	given	O
26	followed	O
26	by	O
26	auto	O
26	-	O
26	PBSCT	O
26	.	O
--------------------------------------------------------------
27	Assessments	O
27	.	O
27	Response	O
27	to	O
27	BD	B-arm_description
27	therapy	O
27	was	O
27	assessed	O
27	using	O
27	the	O
27	IMWG	O
27	uniform	O
27	criteria	O
27	(	O
27	10	O
27	)	O
27	.	O
27	Progression	B-arm_efficacy_metric
27	-	I-arm_efficacy_metric
27	free	I-arm_efficacy_metric
27	survival	I-arm_efficacy_metric
27	(	I-arm_efficacy_metric
27	PFS	I-arm_efficacy_metric
27	)	B-arm_efficacy_metric
27	and	O
27	overall	O
27	survival	O
27	(	O
27	OS	O
27	)	O
27	were	O
27	defined	O
27	as	O
27	the	O
27	time	O
27	from	O
27	starting	O
27	BD	O
27	therapy	O
27	until	O
27	the	O
27	date	O
27	of	O
27	disease	O
27	progression	O
27	and	O
27	death	O
27	,	O
27	respectively	O
27	.	O
27	Adverse	O
27	events	O
27	were	O
27	graded	O
27	using	O
27	the	O
27	National	O
27	Cancer	O
27	Institute	O
27	's	O
27	Common	O
27	Terminology	O
27	Criteria	O
27	for	O
27	Adverse	O
27	Events	O
27	,	O
27	version	O
27	3.0	O
27	(	O
27	11	O
27	)	O
27	.	O
--------------------------------------------------------------
28	Statistical	O
28	analysis	O
28	.	O
28	Response	O
28	rates	O
28	and	O
28	the	O
28	incidence	O
28	of	O
28	any	O
28	adverse	O
28	events	O
28	were	O
28	compared	O
28	using	O
28	Fisher	O
28	's	O
28	exact	O
28	test	O
28	.	O
28	Time	O
28	-	O
28	to	O
28	-	O
28	event	O
28	analysis	O
28	was	O
28	performed	O
28	according	O
28	to	O
28	the	O
28	Kaplan	O
28	-	O
28	Meier	O
28	method	O
28	,	O
28	and	O
28	the	O
28	log	O
28	-	O
28	rank	O
28	test	O
28	was	O
28	applied	O
28	to	O
28	assess	O
28	differences	O
28	between	O
28	subgroups	O
28	.	O
28	A	O
28	value	O
28	of	O
28	p<0.05	O
28	was	O
28	considered	O
28	statistically	O
28	significant	O
28	.	O
--------------------------------------------------------------
29	Patients	O
29	'	O
29	characteristics	O
29	.	O
29	Table	O
29	I	O
29	shows	O
29	the	O
29	characteristics	O
29	of	O
29	the	O
29	22	O
29	patients	O
29	.	O
29	The	O
29	median	O
29	age	O
29	was	O
29	69	O
29	years	O
29	(	O
29	range	O
29	42	O
29	-	O
29	81	O
29	years	O
29	)	O
29	.	O
29	Performance	O
29	status	O
29	(	O
29	PS	O
29	)	O
29	of	O
29	all	O
29	patients	O
29	was	O
29	≥2	O
29	,	O
29	including	O
29	PS	O
29	3	O
29	in	O
29	seven	O
29	patients	O
29	and	O
29	PS	O
29	4	O
29	in	O
29	three	O
29	patients	O
29	.	O
29	Six	O
29	patients	O
29	had	O
29	plasmacytomas	O
29	.	O
29	Three	O
29	patients	O
29	had	O
29	renal	O
29	impairment	O
29	(	O
29	serum	O
29	creatinine	O
29	≥2	O
29	mg	O
29	/	O
29	dl	O
29	)	O
29	.	O
29	The	O
29	median	O
29	time	O
29	from	O
29	diagnosis	O
29	to	O
29	starting	O
29	BD	B-arm_description
29	therapy	O
29	was	O
29	10	O
29	months	O
29	(	O
29	range	O
29	1	O
29	-	O
29	180	O
29	months	O
29	)	O
29	.	O
29	The	O
29	median	O
29	number	O
29	of	O
29	prior	O
29	therapies	O
29	was	O
29	two	O
29	(	O
29	range	O
29	1	O
29	-	O
29	4	O
29	,	O
29	radiotherapy	O
29	was	O
29	counted	O
29	as	O
29	one	O
29	regimen	O
29	)	O
29	.	O
--------------------------------------------------------------
30	Twenty	O
30	-	O
30	one	O
30	had	O
30	received	O
30	corticosteroids	O
30	,	O
30	and	O
30	five	O
30	had	O
30	received	O
30	corticosteroids	O
30	alone	O
30	.	O
30	Fifteen	O
30	had	O
30	received	O
30	melphalan	O
30	-	O
30	containing	O
30	therapy	O
30	.	O
30	One	O
30	had	O
30	received	O
30	high	O
30	-	O
30	dose	O
30	melphalan	O
30	followed	O
30	by	O
30	auto	O
30	-	O
30	PBSCT	O
30	.	O
30	Two	O
30	had	O
30	received	O
30	thalidomide	O
30	.	O
30	Three	O
30	had	O
30	received	O
30	radiotherapy	O
30	.	O
--------------------------------------------------------------
31	Adverse	O
31	events	O
31	.	O
31	to	O
31	continue	O
31	BD	O
31	therapy	O
31	due	O
31	to	O
31	PN	O
31	.	O
31	Pulmonary	O
31	,	O
31	cardiac	O
31	and	O
31	dermatologic	O
31	≥grade	O
31	3	O
31	adverse	O
31	events	O
31	did	O
31	not	O
31	develop	O
31	.	O
31	Herpes	O
31	zoster	O
31	developed	O
31	in	O
31	four	O
31	patients	O
31	without	O
31	prophylaxis	O
31	,	O
31	two	O
31	with	O
31	twice	O
31	-	O
31	weekly	O
31	,	O
31	one	O
31	with	O
31	once	O
31	-	O
31	weekly	O
31	and	O
31	one	O
31	with	O
31	each	O
31	twice	O
31	-	O
31	weekly	O
31	and	O
31	once	O
31	-	O
31	weekly	O
31	administration	O
31	,	O
31	but	O
31	did	O
31	not	O
31	develop	O
31	in	O
31	patients	O
31	who	O
31	received	O
31	prophylactic	O
31	500	O
31	mg	O
31	valaciclovir	O
31	administration	O
31	.	O
--------------------------------------------------------------
32	UCLA	O
32	School	O
32	of	O
32	Medicine	O
32	Los	O
32	Angeles	O
32	CA	O
32	USA	O
32	NatalieCallander	O
32	Department	O
32	of	O
32	Hematology	O
32	University	O
32	of	O
32	Wisconsin	O
32	Madison	O
32	WI	O
32	USA	O
32	JohnLister	O
32	Western	O
32	Pennsylvania	O
32	Hospital	O
32	Pittsburgh	O
32	PA	O
32	MartinOken	O
--------------------------------------------------------------
33	01	O
33	Jul	O
33	2009	O
33	.	O
33	1042	O
33	-	O
33	8194	O
33	(	O
33	Print	O
33	)	O
33	1029	O
33	-	O
33	2403	O
33	01	O
33	Jul	O
33	2009	O
33	.	O
33	01	O
33	Jul	O
33	2009	O
33	.	O
33	10.1080/10428190902748971	O
33	Received	O
33	7	O
33	November	O
33	2008	O
33	;	O
33	revised	O
33	6	O
33	January	O
33	2009	O
33	;	O
33	accepted	O
33	13	O
33	January	O
33	2009	O
--------------------------------------------------------------
34	Dexamethasone	O
34	is	O
34	an	O
34	important	O
34	therapeutic	O
34	agent	O
34	for	O
34	patients	O
34	with	O
34	multiple	O
34	myeloma	O
34	.	O
34	Despite	O
34	high	O
34	initial	O
34	response	O
34	rates	O
34	,	O
34	complete	O
34	responses	O
34	are	O
34	few	O
34	and	O
34	eventually	O
34	all	O
34	patients	O
34	develop	O
34	resistance	O
34	,	O
34	resulting	O
34	in	O
34	a	O
34	compromised	O
34	median	O
34	survival	O
34	of	O
34	2	O
34	-	O
34	3	O
34	years	O
34	[	O
34	1	O
34	]	O
34	.	O
34	Bcl-2	O
34	,	O
34	an	O
34	anti	O
34	-	O
34	apoptotic	O
34	member	O
34	of	O
34	the	O
34	Bcl-2	O
34	family	O
34	of	O
34	proteins	O
34	that	O
34	regulate	O
34	mitochondria	O
34	-	O
34	mediated	O
34	apoptosis	O
34	,	O
34	has	O
34	been	O
34	shown	O
34	to	O
34	be	O
34	a	O
34	key	O
34	factor	O
34	in	O
34	chemotherapy	O
34	resistance	O
34	.	O
34	It	O
34	is	O
34	over	O
34	-	O
34	expressed	O
34	in	O
34	many	O
34	cancers	O
34	[	O
34	2,3	O
34	]	O
34	,	O
34	including	O
34	multiple	O
34	myeloma	O
34	[	O
34	4	O
34	]	O
34	.	O
--------------------------------------------------------------
35	This	O
35	over	O
35	-	O
35	expression	O
35	shifts	O
35	the	O
35	balance	O
35	of	O
35	pro	O
35	-	O
35	apoptotic	O
35	and	O
35	anti	O
35	-	O
35	apoptotic	O
35	proteins	O
35	in	O
35	favour	O
35	of	O
35	the	O
35	latter	O
35	,	O
35	thereby	O
35	preventing	O
35	apoptosis	O
35	induced	O
35	by	O
35	a	O
35	wide	O
35	variety	O
35	of	O
35	cell	O
35	death	O
35	stimuli	O
35	,	O
35	including	O
35	chemotherapeutic	O
35	agents	O
35	,	O
35	antitumor	O
35	antibodies	O
35	and	O
35	radiation	O
35	[	O
35	5,6	O
35	]	O
35	.	O
--------------------------------------------------------------
36	Evidence	O
36	for	O
36	the	O
36	role	O
36	of	O
36	Bcl-2	O
36	in	O
36	the	O
36	development	O
36	of	O
36	resistance	O
36	to	O
36	chemotherapy	O
36	in	O
36	multiple	O
36	myeloma	O
36	has	O
36	been	O
36	found	O
36	in	O
36	a	O
36	variety	O
36	of	O
36	studies	O
36	.	O
36	Several	O
36	groups	O
36	have	O
36	shown	O
36	that	O
36	over	O
36	-	O
36	expression	O
36	of	O
36	Bcl-2	O
36	in	O
36	multiple	O
36	myeloma	O
36	cells	O
36	confers	O
36	resistance	O
36	to	O
36	dexamethasone	O
36	[	O
36	7][8][9][10][11	O
36	]	O
36	and	O
36	paclitaxel	O
36	[	O
36	12	O
36	]	O
36	.	O
36	However	O
36	,	O
36	Bcl-2	O
36	over	O
36	-	O
36	expression	O
36	does	O
36	not	O
36	result	O
36	in	O
36	resistance	O
36	to	O
36	melphalan	O
36	or	O
36	gemcitabine	O
36	,	O
36	drugs	O
36	which	O
36	induce	O
36	apoptosis	O
36	through	O
36	a	O
36	separate	O
36	pathway	O
36	[	O
36	9,12	O
36	]	O
36	.	O
--------------------------------------------------------------
37	Theoretically	O
37	,	O
37	any	O
37	agent	O
37	that	O
37	interferes	O
37	with	O
37	Bcl-2	O
37	expression	O
37	can	O
37	increase	O
37	chemotherapy	O
37	sensitivity	O
37	and/or	O
37	reverse	O
37	resistance	O
37	to	O
37	therapy	O
37	,	O
37	enhancing	O
37	the	O
37	ability	O
37	of	O
37	cytotoxic	O
37	drugs	O
37	such	O
37	as	O
37	dexamethasone	O
37	to	O
37	cause	O
37	cell	O
37	death	O
37	[	O
37	5	O
37	]	O
37	.	O
37	One	O
37	means	O
37	of	O
37	inhibiting	O
37	Bcl-2	O
37	is	O
37	through	O
37	the	O
37	use	O
37	of	O
37	antisense	O
37	therapy	O
37	to	O
37	downregulate	O
37	bcl-2	O
37	mRNA	O
37	,	O
37	thereby	O
37	decreasing	O
37	levels	O
37	of	O
37	Bcl-2	O
37	protein	O
37	.	O
37	Oblimersen	O
37	sodium	O
37	is	O
37	a	O
37	bcl-2	O
37	antisense	O
37	oligonucleotide	O
37	that	O
37	is	O
37	complementary	O
37	to	O
37	the	O
37	first	O
37	six	O
37	codons	O
37	of	O
37	the	O
37	open	O
37	-	O
37	reading	O
37	frame	O
37	of	O
37	bcl-2	O
37	mRNA	O
37	.	O
37	It	O
37	forms	O
37	an	O
37	aberrant	O
37	heteroduplex	O
37	with	O
37	bcl-2	O
37	mRNA	O
37	that	O
37	is	O
37	detected	O
37	and	O
37	cleaved	O
37	by	O
37	RNAse	O
37	-	O
37	H	O
37	,	O
37	resulting	O
37	in	O
37	the	O
37	degradation	O
37	of	O
37	bcl-2	O
37	mRNA	O
37	and	O
37	decreased	O
37	translation	O
37	of	O
37	the	O
37	Bcl-2	O
37	protein	O
37	[	O
37	6,13	O
37	]	O
37	.	O
37	Preclinically	O
37	in	O
37	myeloma	O
37	cells	O
37	,	O
37	oblimersen	O
37	is	O
37	reported	O
37	to	O
37	decrease	O
37	bcl-2	O
37	mRNA	O
37	levels	O
37	and	O
37	significantly	O
37	enhance	O
37	susceptibility	O
37	to	O
37	dexamethasone	O
37	-	O
37	and	O
37	doxorubicin	O
37	-	O
37	induced	O
37	apoptosis	O
37	[	O
37	14	O
37	]	O
37	.	O
--------------------------------------------------------------
38	The	O
38	preclinical	O
38	evidence	O
38	that	O
38	Bcl-2	O
38	overexpression	O
38	in	O
38	myeloma	O
38	cells	O
38	confers	O
38	resistance	O
38	to	O
38	dexamethasone	O
38	and	O
38	that	O
38	oblimersen	O
38	can	O
38	downregulate	O
38	Bcl-2	O
38	protein	O
38	levels	O
38	and	O
38	enhance	O
38	susceptibility	O
38	to	O
38	dexamethasone	O
38	prompted	O
38	us	O
38	to	O
38	investigate	O
38	oblimersen	O
38	in	O
38	multiple	O
38	myeloma	O
38	.	O
38	The	O
38	clinical	B-study_type
38	trial	B-study_type
38	reported	O
38	here	O
38	was	O
38	undertaken	O
38	to	O
38	determine	O
38	the	O
38	role	O
38	of	O
38	oblimersen	O
38	in	O
38	combination	O
38	with	O
38	dexamethasone	O
38	for	O
38	the	O
38	treatment	O
38	of	O
38	patients	O
38	with	O
38	relapsed	O
38	or	O
38	refractory	O
38	multiple	O
38	myeloma	O
38	.	O
--------------------------------------------------------------
39	This	O
39	was	O
39	a	O
39	Phase	B-study_type
39	III	B-study_type
39	,	B-study_type
39	multicentre	I-study_type
39	,	I-study_type
39	randomised	I-study_type
39	,	I-study_type
39	openlabel	I-study_type
39	,	I-study_type
39	parallel	I-study_type
39	-	I-study_type
39	group	I-study_type
39	study	B-study_type
39	designed	O
39	to	O
39	evaluate	O
39	whether	O
39	the	O
39	addition	B-arm_description
39	of	B-arm_description
39	oblimersen	B-arm_description
39	sodium	B-arm_description
39	to	B-arm_description
39	dexamethasone	B-arm_description
39	improved	O
39	clinical	O
39	outcomes	O
39	over	O
39	that	O
39	of	O
39	dexamethasone	B-arm_description
39	alone	B-arm_description
39	in	O
39	patients	O
39	with	O
39	relapsed	O
39	/	O
39	refractory	O
39	multiple	O
39	myeloma	O
39	.	O
--------------------------------------------------------------
40	The	O
40	primary	O
40	objective	O
40	was	O
40	to	O
40	compare	O
40	time	O
40	to	O
40	tumor	O
40	progression	O
40	(	O
40	TTP	O
40	)	O
40	in	O
40	the	O
40	two	O
40	groups	O
40	.	O
40	Key	O
40	secondary	O
40	objectives	O
40	included	O
40	a	O
40	comparison	O
40	of	O
40	the	O
40	treatment	O
40	groups	O
40	with	O
40	respect	O
40	to	O
40	objective	O
40	response	O
40	rate	O
40	,	O
40	duration	O
40	of	O
40	response	O
40	among	O
40	responding	O
40	patients	O
40	and	O
40	survival	O
40	.	O
--------------------------------------------------------------
41	Patients	O
41	enrolled	O
41	with	O
41	multiple	O
41	myeloma	O
41	were	O
41	to	O
41	have	O
41	relapsed	O
41	after	O
41	achieving	O
41	at	O
41	least	O
41	a	O
41	partial	O
41	response	O
41	to	O
41	prior	O
41	therapy	O
41	or	O
41	were	O
41	to	O
41	have	O
41	refractory	O
41	disease	O
41	(	O
41	i.e.	O
41	primary	O
41	resistance	O
41	/	O
41	progressive	O
41	disease	O
41	after	O
41	achieving	O
41	less	O
41	than	O
41	a	O
41	partial	O
41	response	O
41	following	O
41	treatment	O
41	with	O
41	two	O
41	cycles	O
41	of	O
41	chemotherapy	O
41	[	O
41	including	O
41	at	O
41	least	O
41	one	O
41	myelosuppressive	O
41	drug	O
41	]	O
41	)	O
41	within	O
41	the	O
41	3	O
41	months	O
41	prior	O
41	to	O
41	randomisation	B-study_type
41	or	O
41	progressive	O
41	disease	O
41	after	O
41	high	O
41	-	O
41	dose	O
41	chemotherapy	O
41	and	O
41	autologous	O
41	stem	O
41	cell	O
41	transplantation	O
41	.	O
41	Patients	O
41	also	O
41	had	O
41	to	O
41	have	O
41	measurable	O
41	disease	O
41	as	O
41	determined	O
41	by	O
41	serum	O
41	M	O
41	protein	O
41	level	O
41	41.0	O
41	g	O
41	/	O
41	dL	O
41	(	O
41	measured	O
41	by	O
41	serum	O
41	protein	O
41	electrophoresis	O
41	)	O
41	or	O
41	urine	O
41	M	O
41	protein	O
41	excretion	O
41	4200	O
41	mg	O
41	in	O
41	24	O
41	h.	O
--------------------------------------------------------------
42	Other	O
42	requirements	O
42	included	O
42	bone	O
42	marrow	O
42	plasmacytosis	O
42	with	O
42	45	O
42	%	O
42	total	O
42	nucleated	O
42	cells	O
42	;	O
42	prothrombin	O
42	time	O
42	(	O
42	PT	O
42	)	O
42	51.5	O
42	times	O
42	the	O
42	upper	O
42	limit	O
42	of	O
42	normal	O
42	(	O
42	6ULN	O
42	)	O
42	and	O
42	partial	O
42	thromboplastin	O
42	time	O
42	51.5	O
42	6ULN	O
42	;	O
42	creatinine	O
42	1.5	O
42	mg	O
42	/	O
42	dL	O
42	;	O
42	absolute	O
42	neutrophil	O
42	count	O
42	41000	O
42	/	O
42	mL	O
42	;	O
42	platelets	O
42	50	O
42	000	O
42	/	O
42	mL	O
42	;	O
42	and	O
42	ECOG	O
42	performance	O
42	status	O
42	0	O
42	-	O
42	3	O
42	.	O
42	Patients	O
42	were	O
42	excluded	O
42	if	O
42	they	O
42	had	O
42	46	O
42	prior	O
42	treatment	O
42	regimens	O
42	,	O
42	a	O
42	previous	O
42	allogeneic	O
42	stem	O
42	cell	O
42	transplant	O
42	or	O
42	a	O
42	history	O
42	of	O
42	renal	O
42	dialysis	O
42	or	O
42	other	O
42	significant	O
42	medical	O
42	disease	O
42	.	O
--------------------------------------------------------------
43	Eligible	O
43	patients	O
43	were	O
43	stratified	O
43	according	O
43	to	O
43	three	O
43	parameters	O
43	:	O
43	relapse	O
43	after	O
43	response	O
43	vs.	O
43	primary	O
43	resistance	O
43	to	O
43	treatment	O
43	;	O
43	prior	O
43	vs.	O
43	no	O
43	prior	O
43	autologous	O
43	stem	O
43	cell	O
43	transplantation	O
43	and	O
43	one	O
43	to	O
43	two	O
43	prior	O
43	treatment	O
43	regimens	O
43	vs.	O
43	three	O
43	to	O
43	six	O
43	prior	O
43	treatment	O
43	regimens	O
43	.	O
43	Following	O
43	stratification	O
43	,	O
43	they	O
43	were	O
43	centrally	O
43	randomised	B-study_type
43	via	O
43	an	O
43	interactive	O
43	voice	O
43	response	O
43	system	O
43	in	O
43	a	O
43	1:1	B-study_type
43	ratio	B-study_type
43	to	O
43	treatment	O
43	with	O
43	oblimersen	B-arm_description
43	plus	B-arm_description
43	dexamethasone	B-arm_description
43	or	O
43	dexamethasone	B-arm_description
43	alone	B-arm_description
43	.	O
--------------------------------------------------------------
44	Treatment	O
44	was	O
44	administered	O
44	in	O
44	two	O
44	phases	O
44	:	O
44	the	O
44	induction	O
44	period	O
44	(	O
44	cycle	O
44	1	O
44	)	O
44	and	O
44	the	O
44	retreatment	O
44	period	O
44	(	O
44	cycles	O
44	subsequent	O
44	to	O
44	cycle	O
44	1	O
44	)	O
44	.	O
44	Cycle	B-arm_dosage
44	1	I-arm_dosage
44	:	B-arm_dosage
44	during	B-arm_dosage
44	the	I-arm_dosage
44	28-day	I-arm_dosage
44	induction	I-arm_dosage
44	period	I-arm_dosage
44	,	I-arm_dosage
44	patients	I-arm_dosage
44	in	I-arm_dosage
44	the	I-arm_dosage
44	oblimersen/	I-arm_dosage
44	dexamethasone	I-arm_dosage
44	group	I-arm_dosage
44	received	I-arm_dosage
44	oblimersen	I-arm_dosage
44	7	I-arm_dosage
44	mg	I-arm_dosage
44	/	I-arm_dosage
44	kg/	I-arm_dosage
44	day	I-arm_dosage
44	by	I-arm_dosage
44	continuous	I-arm_dosage
44	intravenous	I-arm_dosage
44	infusion	I-arm_dosage
44	for	I-arm_dosage
44	7	I-arm_dosage
44	consecutive	I-arm_dosage
44	days	I-arm_dosage
44	(	I-arm_dosage
44	days	I-arm_dosage
44	1	I-arm_dosage
44	-	I-arm_dosage
44	7	I-arm_dosage
44	)	I-arm_dosage
44	during	I-arm_dosage
44	each	I-arm_dosage
44	of	I-arm_dosage
44	weeks	I-arm_dosage
44	1	I-arm_dosage
44	and	I-arm_dosage
44	3	I-arm_dosage
44	and	I-arm_dosage
44	dexamethasone	I-arm_dosage
44	40	I-arm_dosage
44	mg	I-arm_dosage
44	orally	I-arm_dosage
44	on	I-arm_dosage
44	days	I-arm_dosage
44	4	I-arm_dosage
44	,	I-arm_dosage
44	5	I-arm_dosage
44	,	I-arm_dosage
44	6	I-arm_dosage
44	and	I-arm_dosage
44	7	I-arm_dosage
44	during	I-arm_dosage
44	each	I-arm_dosage
44	of	I-arm_dosage
44	weeks	I-arm_dosage
44	1	I-arm_dosage
44	,	I-arm_dosage
44	2	I-arm_dosage
44	and	I-arm_dosage
44	3	I-arm_dosage
44	.	O
44	Patients	B-arm_dosage
44	in	I-arm_dosage
44	the	I-arm_dosage
44	dexamethasone	I-arm_dosage
44	only	I-arm_dosage
44	group	I-arm_dosage
44	received	I-arm_dosage
44	dexamethasone	I-arm_dosage
44	40	I-arm_dosage
44	mg	I-arm_dosage
44	orally	I-arm_dosage
44	on	I-arm_dosage
44	days	I-arm_dosage
44	1	I-arm_dosage
44	,	I-arm_dosage
44	2	I-arm_dosage
44	,	I-arm_dosage
44	3	I-arm_dosage
44	and	I-arm_dosage
44	4	I-arm_dosage
44	during	I-arm_dosage
44	each	I-arm_dosage
44	of	I-arm_dosage
44	weeks	I-arm_dosage
44	1	I-arm_dosage
44	,	I-arm_dosage
44	2	I-arm_dosage
44	and	I-arm_dosage
44	3	I-arm_dosage
44	.	O
44	No	B-arm_dosage
44	treatment	B-arm_dosage
44	was	I-arm_dosage
44	given	I-arm_dosage
44	during	I-arm_dosage
44	week	I-arm_dosage
44	4	I-arm_dosage
44	to	I-arm_dosage
44	patients	I-arm_dosage
44	in	I-arm_dosage
44	either	I-arm_dosage
44	group	I-arm_dosage
44	.	O
44	Cycles	B-arm_dosage
44	subsequent	I-arm_dosage
44	to	I-arm_dosage
44	cycle	I-arm_dosage
44	1	I-arm_dosage
44	:	B-arm_dosage
44	patients	I-arm_dosage
44	in	I-arm_dosage
44	the	I-arm_dosage
44	combination	I-arm_dosage
44	arm	I-arm_dosage
44	received	I-arm_dosage
44	oblimersen	I-arm_dosage
44	7	I-arm_dosage
44	mg	I-arm_dosage
44	/	I-arm_dosage
44	kg	I-arm_dosage
44	/	I-arm_dosage
44	day	I-arm_dosage
44	by	I-arm_dosage
44	continuous	I-arm_dosage
44	infusion	I-arm_dosage
44	for	I-arm_dosage
44	seven	I-arm_dosage
44	consecutive	I-arm_dosage
44	days	I-arm_dosage
44	(	I-arm_dosage
44	days	I-arm_dosage
44	1	I-arm_dosage
44	-	I-arm_dosage
44	7	I-arm_dosage
44	)	I-arm_dosage
44	and	I-arm_dosage
44	dexamethasone	I-arm_dosage
44	40	I-arm_dosage
44	mg	I-arm_dosage
44	orally	I-arm_dosage
44	on	I-arm_dosage
44	days	I-arm_dosage
44	4	I-arm_dosage
44	,	I-arm_dosage
44	5	I-arm_dosage
44	,	I-arm_dosage
44	6	I-arm_dosage
44	and	I-arm_dosage
44	7	I-arm_dosage
44	during	I-arm_dosage
44	week	I-arm_dosage
44	1	I-arm_dosage
44	.	O
44	Patients	B-arm_dosage
44	in	I-arm_dosage
44	the	I-arm_dosage
44	dexamethasone	I-arm_dosage
44	only	I-arm_dosage
44	group	I-arm_dosage
44	received	I-arm_dosage
44	dexamethasone	I-arm_dosage
44	40	I-arm_dosage
44	mg	I-arm_dosage
44	orally	I-arm_dosage
44	on	I-arm_dosage
44	days	I-arm_dosage
44	1	I-arm_dosage
44	,	I-arm_dosage
44	2	I-arm_dosage
44	,	I-arm_dosage
44	3	I-arm_dosage
44	and	I-arm_dosage
44	4	I-arm_dosage
44	during	I-arm_dosage
44	week	I-arm_dosage
44	1	I-arm_dosage
44	.	O
44	No	O
44	treatment	O
44	was	O
44	given	O
44	during	O
44	weeks	O
44	2	O
44	and	O
44	3	O
44	to	O
44	patients	O
44	in	O
44	either	O
44	group	O
44	.	O
44	Retreatment	O
44	cycles	O
44	were	O
44	repeated	O
44	every	O
44	3	O
44	weeks	O
44	for	O
44	a	O
44	maximum	O
44	of	O
44	1	O
44	year	O
44	in	O
44	patients	O
44	who	O
44	had	O
44	stable	O
44	or	O
44	responsive	O
44	disease	O
44	and	O
44	who	O
44	tolerated	O
44	therapy	O
44	.	O
44	Prophylaxis	O
44	:	O
44	All	O
44	patients	O
44	received	O
44	concomitant	O
44	prophylactic	O
44	treatment	O
44	with	O
44	antibiotics	O
44	,	O
44	histamine	O
44	-	O
44	receptor	O
44	antagonists	O
44	and	O
44	pamidronate	O
44	or	O
44	zoledronic	O
44	acid	O
44	.	O
--------------------------------------------------------------
45	Efficacy	O
45	and	O
45	safety	O
45	evaluations	O
45	were	O
45	performed	O
45	on	O
45	day	O
45	15	O
45	and	O
45	at	O
45	the	O
45	end	O
45	of	O
45	the	O
45	induction	O
45	period	O
45	(	O
45	i.e.	O
45	week	O
45	4	O
45	)	O
45	,	O
45	7	O
45	days	O
45	before	O
45	each	O
45	retreatment	O
45	cycle	O
45	,	O
45	and	O
45	within	O
45	4	O
45	weeks	O
45	after	O
45	withdrawal	O
45	from	O
45	the	O
45	study	O
45	.	O
45	Patients	O
45	were	O
45	followed	O
45	every	O
45	2	O
45	months	O
45	for	O
45	up	O
45	to	O
45	2	O
45	years	O
45	from	O
45	the	O
45	date	O
45	of	O
45	last	O
45	dose	O
45	of	O
45	study	O
45	medication	O
45	.	O
--------------------------------------------------------------
46	The	O
46	primary	O
46	endpoint	O
46	of	O
46	this	O
46	study	O
46	was	O
46	TTP	O
46	,	O
46	which	O
46	was	O
46	calculated	O
46	from	O
46	the	O
46	date	O
46	of	O
46	randomisation	O
46	to	O
46	the	O
46	date	O
46	of	O
46	progression	O
46	and	O
46	was	O
46	determined	O
46	based	O
46	on	O
46	blinded	O
46	clinical	O
46	expert	O
46	review	O
46	by	O
46	S.	O
46	Jagannath	O
46	(	O
46	St.	O
46	Vincent	O
46	's	O
46	Comprehensive	O
46	Cancer	O
46	Centre	O
46	,	O
46	New	O
46	York	O
46	,	O
46	NY	O
46	)	O
46	and	O
46	M	O
46	Oken	O
46	(	O
46	Hubert	O
46	H.	O
46	Humphrey	O
46	Cancer	O
46	Centre	O
46	,	O
46	Robbinsdale	O
46	,	O
46	MN	O
46	)	O
46	.	O
46	Progression	O
46	was	O
46	defined	O
46	as	O
46	the	O
46	first	O
46	of	O
46	the	O
46	following	O
46	events	O
46	to	O
46	occur	O
46	prior	O
46	to	O
46	initiation	O
46	of	O
46	non	O
46	-	O
46	study	O
46	myeloma	O
46	therapy	O
46	:	O
46	objective	O
46	documentation	O
46	of	O
46	progressive	O
46	disease	O
46	,	O
46	death	O
46	within	O
46	60	O
46	days	O
46	of	O
46	the	O
46	last	O
46	evaluation	O
46	of	O
46	objective	O
46	response	O
46	status	O
46	or	O
46	death	O
46	within	O
46	60	O
46	days	O
46	of	O
46	the	O
46	last	O
46	dose	O
46	if	O
46	there	O
46	was	O
46	no	O
46	evaluation	O
46	of	O
46	objective	O
46	response	O
46	status	O
46	.	O
--------------------------------------------------------------
47	Key	O
47	secondary	O
47	endpoints	O
47	included	O
47	objective	O
47	response	O
47	rate	O
47	(	O
47	i.e.	O
47	complete	O
47	response	O
47	,	O
47	response	O
47	[	O
47	75	O
47	%	O
47	improvement	O
47	]	O
47	or	O
47	partial	O
47	response	O
47	as	O
47	assessed	O
47	by	O
47	the	O
47	investigator	O
47	according	O
47	to	O
47	criteria	O
47	adapted	O
47	from	O
47	SWOG	O
47	[	O
47	15	O
47	]	O
47	)	O
47	and	O
47	overall	O
47	survival	O
47	.	O
--------------------------------------------------------------
48	A	O
48	sample	O
48	of	O
48	200	O
48	patients	O
48	(	O
48	100	O
48	per	O
48	treatment	O
48	arm	O
48	)	O
48	was	O
48	required	O
48	to	O
48	provide	O
48	an	O
48	80	O
48	%	O
48	power	O
48	to	O
48	detect	O
48	a	O
48	significant	O
48	difference	O
48	between	O
48	treatment	O
48	groups	O
48	with	O
48	respect	O
48	to	O
48	TTP	O
48	.	O
48	This	O
48	sample	O
48	size	O
48	was	O
48	based	O
48	on	O
48	the	O
48	following	O
48	assumptions	O
48	:	O
48	distributions	O
48	of	O
48	TTP	O
48	for	O
48	the	O
48	two	O
48	treatment	O
48	groups	O
48	would	O
48	be	O
48	compared	O
48	using	O
48	the	O
48	log	O
48	-	O
48	rank	O
48	test	O
48	with	O
48	a	O
48	two	O
48	-	O
48	sided	O
48	significance	O
48	level	O
48	of	O
48	0.05	O
48	;	O
48	median	O
48	TTP	O
48	would	O
48	be	O
48	4	O
48	months	O
48	for	O
48	patients	O
48	who	O
48	received	O
48	dexamethasone	B-arm_description
48	alone	B-arm_description
48	and	O
48	6.33	O
48	months	O
48	for	O
48	patients	O
48	who	O
48	received	O
48	oblimersen	B-arm_description
48	plus	B-arm_description
48	dexamethasone	B-arm_description
48	;	O
48	equal	O
48	numbers	O
48	of	O
48	patients	O
48	would	O
48	be	O
48	assigned	O
48	to	O
48	each	O
48	treatment	O
48	arm	O
48	and	O
48	would	O
48	be	O
48	accrued	O
48	over	O
48	12	O
48	months	O
48	(	O
48	approximately	O
48	18	O
48	per	O
48	month	O
48	)	O
48	with	O
48	a	O
48	6-month	O
48	follow	O
48	-	O
48	up	O
48	period	O
48	after	O
48	enrolment	O
48	of	O
48	the	O
48	last	O
48	patient	O
48	;	O
48	and	O
48	the	O
48	final	O
48	analysis	O
48	would	O
48	be	O
48	performed	O
48	1	O
48	year	O
48	after	O
48	the	O
48	enrolment	O
48	of	O
48	the	O
48	last	O
48	patient	O
48	.	O
48	The	O
48	sample	O
48	estimate	O
48	was	O
48	obtained	O
48	by	O
48	using	O
48	the	O
48	EaSt	O
48	Computer	O
48	Software	O
48	Package	O
48	by	O
48	Cytel	O
48	.	O
48	No	O
48	interim	O
48	analysis	O
48	was	O
48	performed	O
48	.	O
--------------------------------------------------------------
49	The	O
49	primary	O
49	efficacy	O
49	analysis	O
49	was	O
49	a	O
49	comparison	O
49	of	O
49	the	O
49	distributions	O
49	of	O
49	TTP	O
49	between	O
49	the	O
49	two	O
49	treatment	O
49	groups	O
49	in	O
49	the	O
49	intent	O
49	-	O
49	to	O
49	-	O
49	treat	O
49	(	O
49	ITT	O
49	)	O
49	population	O
49	using	O
49	the	O
49	log	O
49	-	O
49	rank	O
49	test	O
49	.	O
49	The	O
49	Cox	O
49	proportional	O
49	hazards	O
49	model	O
49	with	O
49	a	O
49	covariate	O
49	for	O
49	treatment	O
49	was	O
49	used	O
49	to	O
49	estimate	O
49	the	O
49	hazard	O
49	ratio	O
49	for	O
49	TTP	O
49	.	O
--------------------------------------------------------------
50	With	O
50	respect	O
50	to	O
50	key	O
50	secondary	O
50	endpoints	O
50	,	O
50	Fisher	O
50	's	O
50	exact	O
50	test	O
50	was	O
50	used	O
50	to	O
50	compare	O
50	the	O
50	proportion	O
50	of	O
50	patients	O
50	with	O
50	objective	O
50	response	O
50	in	O
50	the	O
50	two	O
50	treatment	O
50	groups	O
50	,	O
50	and	O
50	the	O
50	odds	O
50	ratio	O
50	and	O
50	exact	O
50	95	O
50	%	O
50	confidence	O
50	interval	O
50	also	O
50	were	O
50	provided	O
50	for	O
50	this	O
50	endpoint	O
50	.	O
50	Survival	O
50	time	O
50	was	O
50	calculated	O
50	from	O
50	the	O
50	date	O
50	of	O
50	randomisation	O
50	to	O
50	the	O
50	date	O
50	of	O
50	death	O
50	.	O
50	The	O
50	primary	O
50	analysis	O
50	of	O
50	survival	O
50	was	O
50	to	O
50	occur	O
50	when	O
50	all	O
50	patients	O
50	had	O
50	been	O
50	followed	O
50	for	O
50	2	O
50	years	O
50	after	O
50	the	O
50	end	O
50	of	O
50	treatment	O
50	.	O
--------------------------------------------------------------
51	A	O
51	total	O
51	of	O
51	224	O
51	patients	O
51	comprising	O
51	the	O
51	ITT	O
51	population	O
51	were	O
51	enrolled	O
51	at	O
51	78	O
51	sites	O
51	in	O
51	four	O
51	countries	O
51	(	O
51	72	O
51	sites	O
51	in	O
51	the	O
51	United	O
51	States	O
51	,	O
51	4	O
51	in	O
51	Canada	O
51	and	O
51	1	O
51	each	O
51	in	O
51	England	O
51	and	O
51	France	O
51	)	O
51	.	O
51	The	O
51	first	O
51	patient	O
51	was	O
51	enrolled	O
51	in	O
51	March	O
51	2001	O
51	and	O
51	the	O
51	last	O
51	in	O
51	April	O
51	2003	O
51	.	O
--------------------------------------------------------------
52	One	O
52	hundred	O
52	ten	O
52	patients	O
52	were	O
52	randomised	B-study_type
52	to	O
52	receive	O
52	oblimersen	B-arm_description
52	/	B-arm_description
52	dexamethasone	B-arm_description
52	and	O
52	114	O
52	to	O
52	dexamethasone	B-arm_description
52	alone	B-arm_description
52	.	O
52	Four	O
52	patients	O
52	in	O
52	each	O
52	group	O
52	were	O
52	randomised	O
52	but	O
52	did	O
52	not	O
52	initiate	O
52	treatment	O
52	;	O
52	thus	O
52	,	O
52	the	O
52	safety	O
52	population	O
52	was	O
52	composed	O
52	of	O
52	the	O
52	216	O
52	patients	O
52	who	O
52	received	O
52	treatment	O
52	(	O
52	106	O
52	in	O
52	the	O
52	oblimersen/	O
52	dexamethasone	O
52	group	O
52	and	O
52	110	O
52	in	O
52	the	O
52	dexamethasone	O
52	group	O
52	)	O
52	.	O
52	The	O
52	distribution	O
52	of	O
52	patients	O
52	enrolled	O
52	by	O
52	stratum	O
52	was	O
52	similar	O
52	in	O
52	both	O
52	treatment	O
52	arms	O
52	.	O
--------------------------------------------------------------
53	At	O
53	baseline	O
53	,	O
53	an	O
53	imbalance	O
53	was	O
53	observed	O
53	between	O
53	the	O
53	treatment	O
53	groups	O
53	in	O
53	several	O
53	important	O
53	prognostic	O
53	factors	O
53	(	O
53	Table	O
53	I	O
53	)	O
53	.	O
53	ECOG	O
53	performance	O
53	status	O
53	at	O
53	baseline	O
53	was	O
53	significantly	O
53	worse	O
53	in	O
53	the	O
53	oblimersen/	B-arm_description
53	dexamethasone	B-arm_description
53	group	O
53	(	O
53	p	O
53	¼	O
53	0.028	O
53	)	O
53	.	O
53	In	O
53	addition	O
53	,	O
53	more	O
53	patients	O
53	in	O
53	the	O
53	oblimersen	O
53	/	O
53	dexamethasone	O
53	group	O
53	had	O
53	stage	O
53	III	O
53	disease	O
53	than	O
53	in	O
53	the	O
53	dexamethasone	B-arm_description
53	group	B-arm_description
53	(	O
53	70	O
53	%	O
53	vs.	O
53	61	O
53	%	O
53	,	O
53	respectively	O
53	)	O
53	.	O
53	Also	O
53	,	O
53	imbalances	O
53	in	O
53	baseline	O
53	laboratory	O
53	parameters	O
53	revealed	O
53	that	O
53	patients	O
53	in	O
53	the	O
53	oblimersen	O
53	/	O
53	dexamethasone	O
53	group	O
53	were	O
53	more	O
53	seriously	O
53	impaired	O
53	than	O
53	those	O
53	in	O
53	the	O
53	dexamethasone	O
53	group	O
53	(	O
53	serum	O
53	creatinine	O
53	42.0	O
53	mg	O
53	/	O
53	dL	O
53	:	O
53	5	O
53	%	O
53	and	O
53	0	O
53	%	O
53	,	O
53	respectively	O
53	[	O
53	p	O
53	¼	O
53	0.021	O
53	]	O
53	;	O
53	and	O
53	elevated	O
53	lactate	O
53	dehydrogenase	O
53	:	O
53	23	O
53	%	O
53	and	O
53	11	O
53	%	O
53	,	O
53	respectively	O
53	[	O
53	p	O
53	¼	O
53	0.025	O
53	]	O
53	)	O
53	.	O
--------------------------------------------------------------
54	Patients	O
54	in	O
54	both	O
54	groups	O
54	had	O
54	been	O
54	heavily	O
54	pretreated	O
54	;	O
54	the	O
54	median	O
54	number	O
54	of	O
54	prior	O
54	regimens	O
54	was	O
54	3	O
54	in	O
54	both	O
54	treatment	O
54	groups	O
54	.	O
54	A	O
54	total	O
54	of	O
54	87	O
54	(	O
54	79	O
54	%	O
54	)	O
54	patients	O
54	in	O
54	the	O
54	oblimersen	B-arm_description
54	/	B-arm_description
54	dexamethasone	B-arm_description
54	group	B-arm_description
54	and	O
54	95	O
54	(	O
54	83	O
54	%	O
54	)	O
54	patients	O
54	in	O
54	the	O
54	dexamethasone	B-arm_description
54	group	B-arm_description
54	had	O
54	been	O
54	previously	O
54	treated	O
54	with	O
54	dexamethasone	O
54	;	O
54	47	O
54	and	O
54	51	O
54	of	O
54	these	O
54	patients	O
54	,	O
54	respectively	O
54	,	O
54	had	O
54	been	O
54	refractory	O
54	to	O
54	that	O
54	treatment	O
54	,	O
54	achieving	O
54	a	O
54	response	O
54	not	O
54	better	O
54	than	O
54	stable	O
54	disease	O
54	.	O
--------------------------------------------------------------
55	In	O
55	the	O
55	ITT	O
55	population	O
55	,	O
55	103	O
55	(	O
55	94	O
55	%	O
55	)	O
55	of	O
55	the	O
55	oblimersen/	B-arm_description
55	dexamethasone	B-arm_description
55	group	B-arm_description
55	and	O
55	94	O
55	(	O
55	83	O
55	%	O
55	)	O
55	of	O
55	the	O
55	dexamethasone	B-arm_description
55	group	B-arm_description
55	discontinued	O
55	treatment	O
55	,	O
55	that	O
55	is	O
55	,	O
55	initiated	O
55	516	O
55	cycles	O
55	or	O
55	received	O
55	51	O
55	year	O
55	(	O
55	defined	O
55	as	O
55	335	O
55	days	O
55	)	O
55	of	O
55	protocol	O
55	-	O
55	specified	O
55	therapy	O
55	from	O
55	the	O
55	date	O
55	of	O
55	first	O
55	dose	O
55	.	O
55	Disease	O
55	progression	O
55	/	O
55	lack	O
55	of	O
55	efficacy	O
55	accounted	O
55	for	O
55	more	O
55	than	O
55	50	O
55	%	O
55	of	O
55	the	O
55	discontinuations	O
55	in	O
55	each	O
55	group	O
55	(	O
55	oblimersen	O
55	/	O
55	dexamethasone	O
55	:	O
55	63	O
55	%	O
55	;	O
55	dexamethasone	O
55	:	O
55	55	O
55	%	O
55	)	O
55	.	O
55	Adverse	O
55	event	O
55	/	O
55	toxicity	O
55	was	O
55	the	O
55	second	O
55	most	O
55	frequently	O
55	cited	O
55	reason	O
55	for	O
55	discontinuation	O
55	in	O
55	each	O
55	group	O
55	and	O
55	was	O
55	reported	O
55	for	O
55	16	O
55	%	O
55	of	O
55	patients	O
55	in	O
55	each	O
55	group	O
55	.	O
55	Seven	O
55	percent	O
55	of	O
55	the	O
55	oblimersen	O
55	/	O
55	dexamethasone	O
55	group	O
55	and	O
55	4	O
55	%	O
55	of	O
55	the	O
55	dexamethasone	O
55	group	O
55	discontinued	O
55	for	O
55	other	O
55	reasons	O
55	,	O
55	including	O
55	proceeding	O
55	to	O
55	transplant	O
55	,	O
55	noncompliance	O
55	or	O
55	removal	O
55	based	O
55	on	O
55	physician	O
55	's	O
55	request	O
55	,	O
55	and	O
55	another	O
55	7	O
55	%	O
55	and	O
55	8	O
55	%	O
55	,	O
55	respectively	O
55	,	O
55	either	O
55	withdrew	O
55	consent	O
55	or	O
55	failed	O
55	to	O
55	return	O
55	.	O
--------------------------------------------------------------
56	No	O
56	significant	O
56	difference	O
56	in	O
56	TTP	O
56	was	O
56	observed	O
56	between	O
56	the	O
56	oblimersen	B-arm_description
56	/	B-arm_description
56	dexamethasone	B-arm_description
56	arm	B-arm_description
56	and	O
56	the	O
56	dexamethasone	B-arm_description
56	arm	B-arm_description
56	(	O
56	94	O
56	vs.	O
56	108	O
56	days	O
56	,	O
56	respectively	O
56	;	O
56	p	O
56	¼	O
56	0.26	O
56	)	O
56	(	O
56	Table	O
56	II	O
56	)	O
56	.	O
56	The	O
56	objective	O
56	response	O
56	rates	O
56	in	O
56	the	O
56	two	O
56	groups	O
56	were	O
56	also	O
56	similar	O
56	(	O
56	15	O
56	%	O
56	vs.	O
56	17	O
56	%	O
56	,	O
56	respectively	O
56	)	O
56	(	O
56	Table	O
56	III	O
56	)	O
56	.	O
56	There	O
56	were	O
56	no	O
56	complete	O
56	responses	O
56	as	O
56	defined	O
56	based	O
56	on	O
56	the	O
56	Bladé	O
56	criteria	O
56	,	O
56	[	O
56	16	O
56	]	O
56	and	O
56	no	O
56	differences	O
56	were	O
56	observed	O
56	when	O
56	findings	O
56	were	O
56	analysed	O
56	by	O
56	disease	O
56	stage	O
56	(	O
56	results	O
56	not	O
56	shown	O
56	)	O
56	.	O
56	The	O
56	study	O
56	was	O
56	terminated	O
56	in	O
56	2004	O
56	,	O
56	and	O
56	the	O
56	follow	O
56	-	O
56	up	O
56	of	O
56	patients	O
56	for	O
56	up	O
56	to	O
56	2	O
56	years	O
56	after	O
56	the	O
56	end	O
56	of	O
56	treatment	O
56	was	O
56	not	O
56	completed	O
56	.	O
56	Thus	O
56	,	O
56	the	O
56	analysis	O
56	of	O
56	survival	O
56	included	O
56	data	O
56	available	O
56	through	O
56	a	O
56	cut	O
56	-	O
56	off	O
56	date	O
56	approximately	O
56	1	O
56	year	O
56	after	O
56	enrolment	O
56	of	O
56	the	O
56	last	O
56	subject	O
56	and	O
56	did	O
56	not	O
56	show	O
56	an	O
56	advantage	O
56	of	O
56	oblimersen/	O
56	dexamethasone	O
56	over	O
56	standard	O
56	therapy	O
56	(	O
56	55	O
56	%	O
56	vs.	O
56	42	O
56	%	O
56	of	O
56	treated	O
56	patients	O
56	;	O
56	p	O
56	¼	O
56	0.29	O
56	based	O
56	on	O
56	logistic	O
56	regression	O
56	analysis	O
56	after	O
56	adjustment	O
56	for	O
56	baseline	O
56	imbalances	O
56	)	O
56	.	O
--------------------------------------------------------------
57	All	O
57	treated	O
57	patients	O
57	in	O
57	both	O
57	groups	O
57	had	O
57	at	O
57	least	O
57	one	O
57	adverse	O
57	event	O
57	.	O
57	The	O
57	most	O
57	common	O
57	adverse	O
57	event	O
57	in	O
57	both	O
57	treatment	O
57	groups	O
57	was	O
57	fatigue	O
57	,	O
57	occurring	O
57	in	O
57	54	O
57	%	O
57	of	O
57	the	O
57	patients	O
57	receiving	O
57	oblimersen	B-arm_description
57	/	B-arm_description
57	dexamethasone	B-arm_description
57	and	O
57	45	O
57	%	O
57	of	O
57	those	B-arm_description
57	receiving	B-arm_description
57	dexamethasone	B-arm_description
57	.	O
57	Other	O
57	adverse	O
57	events	O
57	occurring	O
57	in	O
57	25	O
57	%	O
57	of	O
57	the	O
57	patients	O
57	in	O
57	the	O
57	oblimersen	O
57	/	O
57	dexamethasone	O
57	group	O
57	were	O
57	fever	O
57	(	O
57	48	O
57	%	O
57	)	O
57	,	O
57	nausea	O
57	(	O
57	41	O
57	%	O
57	)	O
57	,	O
57	insomnia	O
57	(	O
57	35	O
57	%	O
57	)	O
57	,	O
57	anemia	O
57	(	O
57	33	O
57	%	O
57	)	O
57	,	O
57	arthralgia	O
57	(	O
57	31	O
57	%	O
57	)	O
57	,	O
57	constipation	O
57	(	O
57	31	O
57	%	O
57	)	O
57	,	O
57	diarrhea	O
57	(	O
57	27	O
57	%	O
57	)	O
57	and	O
57	vomiting	O
57	(	O
57	25	O
57	%	O
57	)	O
57	.	O
57	In	O
57	the	O
57	dexamethasone	O
57	group	O
57	,	O
57	insomnia	O
57	(	O
57	34	O
57	%	O
57	)	O
57	and	O
57	weakness	O
57	(	O
57	25	O
57	%	O
57	)	O
57	were	O
57	the	O
57	only	O
57	adverse	O
57	events	O
57	besides	O
57	fatigue	O
57	that	O
57	occurred	O
57	in	O
57	25	O
57	%	O
57	of	O
57	patients	O
57	(	O
57	Table	O
57	IV	O
57	)	O
57	.	O
57	The	O
57	percentage	O
57	of	O
57	patients	O
57	who	O
57	discontinued	O
57	because	O
57	of	O
57	an	O
57	adverse	O
57	event	O
57	was	O
57	the	O
57	same	O
57	in	O
57	both	O
57	arms	O
57	(	O
57	16	O
57	%	O
57	)	O
57	;	O
57	events	O
57	that	O
57	resulted	O
57	in	O
57	discontinuation	O
57	and	O
57	were	O
57	considered	O
57	to	O
57	be	O
57	treatment	O
57	related	O
57	were	O
57	reported	O
57	for	O
57	12	O
57	%	O
57	of	O
57	patients	O
57	in	O
57	the	O
57	oblimersen/	O
57	dexamethasone	O
57	group	O
57	and	O
57	14	O
57	%	O
57	of	O
57	patients	O
57	in	O
57	the	O
57	dexamethasone	O
57	group	O
57	.	O
57	In	O
57	both	O
57	groups	O
57	,	O
57	half	O
57	of	O
57	the	O
57	patients	O
57	who	O
57	discontinued	O
57	due	O
57	to	O
57	an	O
57	adverse	O
57	event	O
57	did	O
57	so	O
57	in	O
57	cycle	O
57	1	O
57	.	O
57	No	O
57	single	O
57	adverse	O
57	event	O
57	or	O
57	cluster	O
57	of	O
57	adverse	O
57	events	O
57	resulted	O
57	in	O
57	cycle	O
57	1	O
57	discontinuations	O
57	.	O
--------------------------------------------------------------
58	Renal	O
58	and	O
58	hematologic	O
58	toxicities	O
58	.	O
58	An	O
58	increase	O
58	in	O
58	blood	O
58	creatinine	O
58	was	O
58	noted	O
58	in	O
58	25	O
58	%	O
58	of	O
58	the	O
58	oblimersen/	O
58	dexamethasone	O
58	patients	O
58	and	O
58	15	O
58	%	O
58	of	O
58	the	O
58	dexamethasone	O
58	patients	O
58	,	O
58	and	O
58	was	O
58	Grade	O
58	3	O
58	or	O
58	4	O
58	in	O
58	8	O
58	%	O
58	and	O
58	4	O
58	%	O
58	,	O
58	respectively	O
58	(	O
58	Table	O
58	IV	O
58	)	O
58	.	O
58	In	O
58	both	O
58	treatment	O
58	groups	O
58	,	O
58	increase	O
58	in	O
58	blood	O
58	creatinine	O
58	was	O
58	more	O
58	likely	O
58	to	O
58	occur	O
58	in	O
58	patients	O
58	with	O
58	elevated	O
58	baseline	O
58	serum	O
58	creatinine	O
58	(	O
58	41.5	O
58	mg	O
58	/	O
58	dL	O
58	)	O
58	and	O
58	in	O
58	patients	O
58	who	O
58	were	O
58	black	O
58	and/or	O
58	had	O
58	concurrent	O
58	medical	O
58	conditions	O
58	that	O
58	affect	O
58	renal	O
58	function	O
58	,	O
58	such	O
58	as	O
58	diabetes	O
58	or	O
58	hypertension	O
58	.	O
58	Despite	O
58	the	O
58	increased	O
58	percentage	O
58	of	O
58	patients	O
58	in	O
58	the	O
58	oblimersen	B-arm_description
58	/	B-arm_description
58	dexamethasone	B-arm_description
58	group	B-arm_description
58	with	O
58	increased	O
58	blood	O
58	creatinine	O
58	,	O
58	the	O
58	incidence	O
58	of	O
58	patients	O
58	experiencing	O
58	renal	O
58	failure	O
58	was	O
58	comparable	O
58	in	O
58	the	O
58	two	O
58	groups	O
58	(	O
58	oblimersen/	O
58	dexamethasone	O
58	:	O
58	three	O
58	[	O
58	3	O
58	%	O
58	]	O
58	patients	O
58	;	O
58	dexamethasone	B-arm_description
58	:	O
58	four	O
58	[	O
58	4	O
58	%	O
58	]	O
58	patients	O
58	)	O
58	.	O
58	Includes	O
58	adverse	O
58	events	O
58	(	O
58	regardless	O
58	of	O
58	relationship	O
58	to	O
58	treatment	O
58	)	O
58	that	O
58	occurred	O
58	in	O
58	20	O
58	%	O
58	of	O
58	patients	O
58	in	O
58	either	O
58	treatment	O
58	group	O
58	.	O
--------------------------------------------------------------
59	Thrombocytopenia	O
59	was	O
59	observed	O
59	in	O
59	22	O
59	%	O
59	of	O
59	oblimersen	B-arm_description
59	/	B-arm_description
59	dexamethasone	B-arm_description
59	patients	O
59	and	O
59	9	O
59	%	O
59	of	O
59	dexamethasone	B-arm_description
59	patients	B-arm_description
59	and	O
59	was	O
59	Grade	O
59	3	O
59	or	O
59	Grade	O
59	4	O
59	in	O
59	14	O
59	%	O
59	and	O
59	5	O
59	%	O
59	,	O
59	respectively	O
59	.	O
59	The	O
59	incidence	O
59	of	O
59	Grade	O
59	3	O
59	or	O
59	4	O
59	bleeding	O
59	events	O
59	was	O
59	similar	O
59	in	O
59	the	O
59	two	O
59	treatment	O
59	groups	O
59	(	O
59	6	O
59	%	O
59	and	O
59	5	O
59	%	O
59	,	O
59	respectively	O
59	)	O
59	.	O
59	In	O
59	both	O
59	groups	O
59	,	O
59	the	O
59	incidence	O
59	of	O
59	Grade	O
59	3	O
59	or	O
59	Grade	O
59	4	O
59	anemia	O
59	was	O
59	12	O
59	%	O
59	and	O
59	the	O
59	incidence	O
59	of	O
59	Grade	O
59	3	O
59	or	O
59	Grade	O
59	4	O
59	neutropenia	O
59	was	O
59	4	O
59	%	O
59	.	O
--------------------------------------------------------------
60	Deaths	O
60	.	O
60	The	O
60	incidence	O
60	of	O
60	adverse	O
60	events	O
60	with	O
60	an	O
60	outcome	O
60	of	O
60	death	O
60	during	O
60	treatment	O
60	or	O
60	within	O
60	30	O
60	days	O
60	of	O
60	the	O
60	end	O
60	of	O
60	treatment	O
60	was	O
60	similar	O
60	in	O
60	the	O
60	two	O
60	treatment	O
60	groups	O
60	(	O
60	oblimersen	B-arm_description
60	/	B-arm_description
60	dexamethasone	B-arm_description
60	:	O
60	13	O
60	(	O
60	12	O
60	%	O
60	)	O
60	;	O
60	dexamethasone	B-arm_description
60	:	O
60	10	O
60	(	O
60	9	O
60	%	O
60	)	O
60	(	O
60	Table	O
60	V	O
60	)	O
60	.	O
60	Disease	O
60	progression	O
60	was	O
60	the	O
60	most	O
60	frequently	O
60	reported	O
60	cause	O
60	of	O
60	death	O
60	,	O
60	accounting	O
60	for	O
60	five	O
60	deaths	O
60	in	O
60	the	O
60	combination	O
60	arm	O
60	and	O
60	three	O
60	deaths	O
60	in	O
60	the	O
60	dexamethasone	O
60	arm	O
60	.	O
--------------------------------------------------------------
61	Impact	O
61	of	O
61	high	O
61	-	O
61	risk	O
61	cytogenetics	O
61	and	O
61	prior	O
61	therapy	O
61	on	O
61	outcomes	O
61	in	O
61	patients	O
61	with	O
61	advanced	O
61	relapsed	O
61	or	O
61	refractory	O
61	multiple	O
61	myeloma	O
61	treated	O
61	with	O
61	lenalidomide	B-arm_description
61	plus	B-arm_description
61	dexaméthasone	B-arm_description
61	Impact	O
61	of	O
61	high	O
61	-	O
61	risk	O
61	cytogenetics	O
61	and	O
61	prior	O
61	therapy	O
61	on	O
61	outcomes	O
61	in	O
61	patients	O
61	with	O
61	advanced	O
61	relapsed	O
61	or	O
61	refractory	O
61	multiple	O
61	myeloma	O
61	treated	O
61	with	O
61	lenalidomide	O
61	plus	O
61	dexaméthasone	O
61	14	O
61	January	O
61	2010	O
61	14	O
61	January	O
61	2010	O
61	ProfessorHAvet	B-authors
61	-	B-authors
61	Loiseau	B-authors
--------------------------------------------------------------
62	Assistance	O
62	Publique	O
62	-	O
62	Hô	O
62	pitaux	O
62	de	O
62	Paris	O
62	Paris	O
62	France	O
62	IYakoub	B-authors
62	-	B-authors
62	Agha	B-authors
62	Hematology	O
62	Department	O
62	University	O
62	Hospital	O
62	Huriez	O
62	Lille	O
62	France	O
62	MAttal	B-authors
62	Hematology	O
62	Department	O
62	Centre	O
62	Hospitalier	O
62	Purpan	O
62	Toulouse	O
62	France	O
62	CHulin	B-authors
62	Hematology	O
62	Department	O
62	University	O
62	Hospital	O
62	Brabois	O
62	Nancy	O
62	France	O
62	LGarderet	B-authors
62	Hematology	O
62	Department	O
--------------------------------------------------------------
63	Impact	O
63	of	O
63	high	O
63	-	O
63	risk	O
63	cytogenetics	O
63	and	O
63	prior	O
63	therapy	O
63	on	O
63	outcomes	O
63	in	O
63	patients	O
63	with	O
63	advanced	O
63	relapsed	O
63	or	O
63	refractory	O
63	multiple	O
63	myeloma	O
63	treated	O
63	with	O
63	lenalidomide	B-arm_description
63	plus	B-arm_description
63	dexaméthasone	B-arm_description
63	14	O
63	January	O
63	2010	O
63	10.1038	O
63	/	O
63	leu.2009.273	O
--------------------------------------------------------------
64	Impact	O
64	of	O
64	high	O
64	-	O
64	risk	O
64	cytogenetics	O
64	and	O
64	prior	O
64	therapy	O
64	on	O
64	outcomes	O
64	in	O
64	patients	O
64	with	O
64	advanced	O
64	relapsed	O
64	or	O
64	refractory	O
64	multiple	O
64	myeloma	O
64	treated	O
64	with	O
64	lenalidomide	B-arm_description
64	plus	B-arm_description
64	dexaméthasone	I-arm_description
64	ProfessorHAvet	B-authors
64	-	B-authors
64	Loiseau	B-authors
64	herve.avetloiseau@chu-nantes.fr	O
--------------------------------------------------------------
65	France	O
65	ProfessorHAvet	B-authors
65	-	B-authors
65	Loiseau	B-authors
65	Professor	O
65	H	O
65	Avet	O
65	-	O
65	Loiseau	O
65	herve.avetloiseau@chu-nantes.fr	O
65	Institut	O
65	National	O
65	de	O
65	la	O
65	Santé	O
65	et	O
65	de	O
65	la	O
65	Recherche	O
65	Médicale	O
65	(	O
65	INSERM	O
65	)	O
65	Unité	O
65	892	O
65	Nantes	O
--------------------------------------------------------------
66	France	O
66	9	O
66	quai	O
66	Moncouscu	O
66	44093	O
66	Nantes	O
66	France	O
66	Impact	O
66	of	O
66	high	O
66	-	O
66	risk	O
66	cytogenetics	O
66	and	O
66	prior	O
66	therapy	O
66	on	O
66	outcomes	O
66	in	O
66	patients	O
66	with	O
66	advanced	O
66	relapsed	O
66	or	O
66	refractory	O
66	multiple	O
66	myeloma	O
66	treated	O
66	with	O
66	lenalidomide	B-arm_description
66	plus	I-arm_description
66	dexaméthasone	I-arm_description
66	14	O
66	January	O
66	2010	O
66	14	O
66	January	O
66	2010	O
66	14	O
66	January	O
66	2010	O
66	10.1038	O
66	/	O
66	leu.2009.273	O
66	Received	O
66	6	O
66	May	O
66	2009	O
66	;	O
66	revised	O
66	29	O
66	October	O
66	2009	O
66	;	O
66	accepted	O
66	9	O
66	November	O
66	2009	O
66	;	O
--------------------------------------------------------------
67	Multiple	O
67	myeloma	O
67	(	O
67	MM	O
67	)	O
67	is	O
67	a	O
67	common	O
67	hematological	O
67	malignancy	O
67	,	O
67	which	O
67	accounts	O
67	for	O
67	B2	O
67	%	O
67	of	O
67	all	O
67	cancer	O
67	deaths	O
67	according	O
67	to	O
67	recent	O
67	US	O
67	statistics	O
67	.	O
67	1	O
67	It	O
67	is	O
67	an	O
67	incurable	O
67	disease	O
67	,	O
67	but	O
67	with	O
67	the	O
67	introduction	O
67	of	O
67	novel	O
67	therapies	O
67	,	O
67	such	O
67	as	O
67	thalidomide	O
67	,	O
67	lenalidomide	O
67	,	O
67	and	O
67	bortezomib	O
67	,	O
67	median	O
67	survival	O
67	has	O
67	doubled	O
67	to	O
67	B4	O
67	-	O
67	5	O
67	years	O
67	and	O
67	patients	O
67	now	O
67	have	O
67	a	O
67	20	O
67	%	O
67	chance	O
67	of	O
67	surviving	O
67	longer	O
67	than	O
67	10	O
67	years	O
67	.	O
67	2	O
67	Lenalidomide	O
67	(	O
67	Revlimid	O
67	;	O
67	Celgene	O
67	Corporation	O
67	,	O
67	Summit	O
67	,	O
67	NJ	O
67	,	O
67	USA	O
67	)	O
67	in	O
67	combination	O
67	with	O
67	dexamethasone	O
67	was	O
67	shown	O
67	to	O
67	be	O
67	highly	O
67	effective	O
67	in	O
67	the	O
67	treatment	O
67	of	O
67	patients	O
67	with	O
67	relapsed	O
67	or	O
67	refractory	O
67	MM	O
67	3,4	O
67	and	O
67	has	O
67	been	O
67	approved	O
67	in	O
67	the	O
67	European	O
67	Union	O
67	and	O
67	the	O
67	United	O
67	States	O
67	for	O
67	the	O
67	treatment	O
67	of	O
67	patients	O
67	with	O
67	MM	O
67	who	O
67	have	O
67	received	O
67	at	O
67	least	O
67	one	O
67	prior	O
67	therapy	O
67	.	O
--------------------------------------------------------------
68	The	O
68	chromosomal	O
68	abnormalities	O
68	of	O
68	del	O
68	(	O
68	13	O
68	)	O
68	,	O
68	t	O
68	(	O
68	4;14	O
68	)	O
68	,	O
68	and	O
68	del(17p	O
68	)	O
68	are	O
68	associated	O
68	with	O
68	poor	O
68	progression	O
68	-	O
68	free	O
68	survival	O
68	(	O
68	PFS	O
68	)	O
68	and	O
68	shorter	O
68	overall	O
68	survival	O
68	(	O
68	OS	O
68	)	O
68	in	O
68	newly	O
68	diagnosed	O
68	MM	O
68	patients	O
68	treated	O
68	with	O
68	traditional	O
68	chemotherapy	O
68	.	O
68	[	O
68	5][6][7][8	O
68	]	O
68	It	O
68	was	O
68	earlier	O
68	reported	O
68	that	O
68	newly	O
68	diagnosed	O
68	MM	O
68	patients	O
68	with	O
68	an	O
68	abnormal	O
68	karyotype	O
68	treated	O
68	with	O
68	lenalidomide	O
68	plus	O
68	dexamethasone	O
68	had	O
68	a	O
68	lower	O
68	PFS	O
68	and	O
68	OS	O
68	compared	O
68	with	O
68	patients	O
68	with	O
68	a	O
68	normal	O
68	karyotype	O
68	.	O
68	9	O
68	Preliminary	O
68	results	O
68	from	O
68	a	O
68	study	O
68	in	O
68	patients	O
68	with	O
68	relapsed	O
68	and	O
68	refractory	O
68	MM	O
68	treated	O
68	with	O
68	lenalidomide	O
68	plus	O
68	dexamethasone	O
68	showed	O
68	that	O
68	this	O
68	combination	O
68	can	O
68	overcome	O
68	the	O
68	poor	O
68	prognosis	O
68	conferred	O
68	by	O
68	the	O
68	chromosomal	O
68	abnormalities	O
68	of	O
68	del	O
68	(	O
68	13	O
68	)	O
68	and	O
68	t	O
68	(	O
68	4;14	O
68	)	O
68	,	O
68	but	O
68	not	O
68	del(17p	O
68	)	O
68	.	O
68	10	O
68	In	O
68	contrast	O
68	,	O
68	a	O
68	recent	O
68	analysis	O
68	of	O
68	100	O
68	patients	O
68	treated	O
68	with	O
68	lenalidomide	O
68	plus	O
68	dexamethasone	O
68	at	O
68	diagnosis	O
68	revealed	O
68	that	O
68	this	O
68	combination	O
68	was	O
68	not	O
68	able	O
68	to	O
68	overcome	O
68	the	O
68	poor	O
68	prognosis	O
68	of	O
68	chromosomal	O
68	abnormalities	O
68	and	O
68	high	O
68	labeling	O
68	index	O
68	.	O
68	11	O
68	The	O
68	prognostic	O
68	value	O
68	of	O
68	these	O
68	cytogenetic	O
68	abnormalities	O
68	and	O
68	the	O
68	impact	O
68	of	O
68	prior	O
68	therapy	O
68	in	O
68	the	O
68	relapsed	O
68	and	O
68	refractory	O
68	setting	O
68	remain	O
68	to	O
68	be	O
68	fully	O
68	defined	O
68	.	O
--------------------------------------------------------------
69	We	O
69	performed	O
69	a	O
69	retrospective	B-study_type
69	analysis	B-study_type
69	to	O
69	investigate	O
69	the	O
69	prognostic	O
69	values	O
69	of	O
69	del	O
69	(	O
69	13	O
69	)	O
69	,	O
69	t	O
69	(	O
69	4;14	O
69	)	O
69	,	O
69	and	O
69	del(17p	O
69	)	O
69	and	O
69	the	O
69	impact	O
69	of	O
69	prior	O
69	treatment	O
69	on	O
69	outcomes	O
69	in	O
69	relapsed	O
69	or	O
69	refractory	O
69	MM	O
69	patients	O
69	treated	O
69	with	O
69	lenalidomide	B-arm_description
69	plus	B-arm_description
69	dexamethasone	B-arm_description
69	.	O
--------------------------------------------------------------
70	Temporary	O
70	Authorization	O
70	for	O
70	Use	O
70	,	O
70	is	O
70	the	O
70	regulatory	O
70	mechanism	O
70	used	O
70	by	O
70	the	O
70	French	O
70	Health	O
70	Products	O
70	and	O
70	Safety	O
70	Agency	O
70	,	O
70	which	O
70	allows	O
70	access	O
70	of	O
70	non	O
70	-	O
70	approved	O
70	drugs	O
70	to	O
70	patients	O
70	in	O
70	France	O
70	,	O
70	on	O
70	a	O
70	named	O
70	-	O
70	patient	O
70	basis	O
70	.	O
70	Medical	B-study_type
70	records	B-study_type
70	were	I-study_type
70	obtained	I-study_type
70	from	O
70	49	O
70	clinical	O
70	centers	O
70	participating	O
70	in	O
70	the	O
70	French	O
70	Autorisation	O
70	Temporaire	O
70	d'Utilisation	O
70	program	O
70	.	O
--------------------------------------------------------------
71	Patients	O
71	with	O
71	relapsed	O
71	or	O
71	refractory	O
71	MM	O
71	who	O
71	had	O
71	earlier	O
71	received	O
71	alkylating	O
71	agents	O
71	as	O
71	well	O
71	as	O
71	prior	O
71	thalidomide	O
71	and/or	O
71	bortezomib	O
71	and	O
71	patients	O
71	with	O
71	available	O
71	fluorescence	O
71	in	O
71	situ	O
71	hybridization	O
71	(	O
71	FISH	O
71	)	O
71	data	O
71	were	O
71	included	O
71	in	O
71	the	O
71	analysis	O
71	.	O
71	Patients	O
71	received	O
71	oral	B-arm_dosage
71	treatment	B-arm_dosage
71	with	B-arm_dosage
71	lenalidomide	B-arm_dosage
71	(	B-arm_dosage
71	25	I-arm_dosage
71	mg	I-arm_dosage
71	per	I-arm_dosage
71	day	I-arm_dosage
71	on	I-arm_dosage
71	days	I-arm_dosage
71	1	I-arm_dosage
71	-	I-arm_dosage
71	21	I-arm_dosage
71	of	I-arm_dosage
71	every	I-arm_dosage
71	28-day	I-arm_dosage
71	cycle	I-arm_dosage
71	)	I-arm_dosage
71	plus	I-arm_dosage
71	dexamethasone	I-arm_dosage
71	(	I-arm_dosage
71	40	I-arm_dosage
71	mg	I-arm_dosage
71	per	I-arm_dosage
71	day	I-arm_dosage
71	on	I-arm_dosage
71	days	I-arm_dosage
71	1	I-arm_dosage
71	-	I-arm_dosage
71	4	I-arm_dosage
71	,	I-arm_dosage
71	9	I-arm_dosage
71	-	I-arm_dosage
71	12	I-arm_dosage
71	,	I-arm_dosage
71	and	I-arm_dosage
71	17	I-arm_dosage
71	-	I-arm_dosage
71	20	I-arm_dosage
71	for	I-arm_dosage
71	four	I-arm_dosage
71	cycles	I-arm_dosage
71	,	I-arm_dosage
71	then	I-arm_dosage
71	days	I-arm_dosage
71	1	I-arm_dosage
71	-	I-arm_dosage
71	4	I-arm_dosage
71	beginning	I-arm_dosage
71	with	I-arm_dosage
71	cycle	I-arm_dosage
71	5	I-arm_dosage
71	)	I-arm_dosage
71	.	O
--------------------------------------------------------------
72	At	O
72	enrolment	O
72	,	O
72	FISH	O
72	cytogenetic	O
72	analysis	O
72	was	O
72	performed	O
72	by	O
72	two	O
72	laboratories	O
72	(	O
72	in	O
72	Nantes	O
72	and	O
72	Paris	O
72	)	O
72	.	O
72	CD138-purified	O
72	plasma	O
72	cells	O
72	were	O
72	analyzed	O
72	for	O
72	del	O
72	(	O
72	13	O
72	)	O
72	,	O
72	t	O
72	(	O
72	4;14	O
72	)	O
72	,	O
72	and	O
72	del(17p	O
72	)	O
72	as	O
72	described	O
72	earlier	O
72	.	O
72	6	O
72	Response	O
72	and	O
72	disease	O
72	progression	O
72	endpoints	O
72	were	O
72	evaluated	O
72	using	O
72	the	O
72	European	O
72	Group	O
72	for	O
72	Blood	O
72	and	O
72	Marrow	O
72	Transplantation	O
72	criteria	O
72	.	O
72	12,13	O
72	OS	O
72	data	O
72	were	O
72	collected	O
72	at	O
72	the	O
72	time	O
72	of	O
72	the	O
72	patients	O
72	'	O
72	last	O
72	visit	O
72	.	O
--------------------------------------------------------------
73	The	O
73	independent	O
73	prognostic	O
73	impact	O
73	of	O
73	the	O
73	chromosomal	O
73	abnormalities	O
73	del(13	O
73	)	O
73	and	O
73	t	O
73	(	O
73	4;14	O
73	)	O
73	was	O
73	analyzed	O
73	by	O
73	comparing	O
73	the	O
73	outcomes	O
73	(	O
73	overall	O
73	response	O
73	rate	O
73	[	O
73	ORR	O
73	]	O
73	,	O
73	PFS	B-arm_efficacy_metric
73	,	O
73	and	O
73	OS	O
73	)	O
73	of	O
73	patients	O
73	with	O
73	or	O
73	without	O
73	the	O
73	respective	O
73	abnormality	O
73	.	O
73	Patient	O
73	response	O
73	and	O
73	survival	O
73	according	O
73	to	O
73	the	O
73	presence	O
73	or	O
73	absence	O
73	of	O
73	del(17p	O
73	)	O
73	were	O
73	not	O
73	evaluable	O
73	because	O
73	of	O
73	the	O
73	small	O
73	number	O
73	of	O
73	patients	O
73	with	O
73	del(17p	O
73	)	O
73	(	O
73	n	O
73	¼	O
73	8)	O
73	.	O
73	The	O
73	w	O
73	2	O
73	tests	O
73	,	O
73	Fisher	O
73	's	O
73	exact	O
73	test	O
73	,	O
73	and	O
73	logistic	O
73	regression	O
73	were	O
73	used	O
73	to	O
73	compare	O
73	ORR	O
73	between	O
73	groups	O
73	.	O
73	Time	O
73	-	O
73	to	O
73	-	O
73	event	O
73	variables	O
73	were	O
73	estimated	O
73	by	O
73	Kaplan	O
73	-	O
73	Meier	O
73	methods	O
73	.	O
73	Two	O
73	-	O
73	sided	O
73	log	O
73	-	O
73	rank	O
73	tests	O
73	were	O
73	used	O
73	to	O
73	compare	O
73	survivorship	O
73	functions	O
73	between	O
73	groups	O
73	.	O
--------------------------------------------------------------
74	Multivariate	O
74	analyses	O
74	using	O
74	Cox	O
74	proportional	O
74	-	O
74	hazard	O
74	regression	O
74	model	O
74	were	O
74	performed	O
74	to	O
74	assess	O
74	the	O
74	impact	O
74	of	O
74	the	O
74	following	O
74	variables	O
74	on	O
74	ORR	O
74	,	O
74	PFS	B-arm_efficacy_metric
74	,	O
74	and	O
74	OS	O
74	:	O
74	age	O
74	,	O
74	sex	O
74	,	O
74	hemoglobin	O
74	level	O
74	,	O
74	presence	O
74	of	O
74	del	O
74	(	O
74	13	O
74	)	O
74	,	O
74	presence	O
74	of	O
74	t	O
74	(	O
74	4;14	O
74	)	O
74	,	O
74	prior	O
74	bortezomib	O
74	treatment	O
74	,	O
74	prior	O
74	thalidomide	O
74	treatment	O
74	,	O
74	progression	O
74	on	O
74	thalidomide	O
74	,	O
74	prior	O
74	stem	O
74	cell	O
74	transplant	O
74	,	O
74	and	O
74	number	O
74	of	O
74	lines	O
74	of	O
74	earlier	O
74	therapy	O
74	.	O
74	Age	O
74	,	O
74	hemoglobin	O
74	,	O
74	and	O
74	number	O
74	of	O
74	lines	O
74	of	O
74	earlier	O
74	therapy	O
74	were	O
74	continuous	O
74	variables	O
74	;	O
74	all	O
74	other	O
74	variables	O
74	were	O
74	dichotomous	O
74	.	O
74	The	O
74	thresholds	O
74	for	O
74	entry	O
74	and	O
74	stay	O
74	were	O
74	0.25	O
74	and	O
74	0.15	O
74	,	O
74	respectively	O
74	.	O
--------------------------------------------------------------
75	Of	O
75	228	O
75	eligible	O
75	patients	O
75	,	O
75	207	O
75	patients	O
75	enrolled	O
75	in	O
75	the	O
75	Autorisation	O
75	Temporaire	O
75	d'Utilisation	O
75	program	O
75	between	O
75	April	O
75	2006	O
75	and	O
75	March	O
75	2007	O
75	were	O
75	included	O
75	in	O
75	this	O
75	analysis	O
75	.	O
75	The	O
75	remaining	O
75	21	O
75	patients	O
75	were	O
75	excluded	O
75	either	O
75	because	O
75	of	O
75	early	O
75	death	O
75	before	O
75	the	O
75	end	O
75	of	O
75	the	O
75	first	O
75	cycle	O
75	(	O
75	n	O
75	¼	O
75	14	O
75	)	O
75	or	O
75	because	O
75	of	O
75	patient	O
75	or	O
75	physician	O
75	refusal	O
75	for	O
75	continued	O
75	participation	O
75	(	O
75	n	O
75	¼	O
75	7	O
75	)	O
75	.	O
--------------------------------------------------------------
76	FISH	O
76	data	O
76	for	O
76	del	O
76	(	O
76	13	O
76	)	O
76	were	O
76	available	O
76	in	O
76	92	O
76	%	O
76	(	O
76	191	O
76	of	O
76	207	O
76	)	O
76	of	O
76	patients	O
76	,	O
76	for	O
76	t	O
76	(	O
76	4;14	O
76	)	O
76	in	O
76	89	O
76	%	O
76	(	O
76	184	O
76	of	O
76	207	O
76	)	O
76	of	O
76	patients	O
76	,	O
76	and	O
76	for	O
76	del(17p	O
76	)	O
76	in	O
76	58	O
76	%	O
76	(	O
76	120	O
76	of	O
76	207	O
76	)	O
76	of	O
76	patients	O
76	.	O
76	Del	O
76	(	O
76	13	O
76	)	O
76	was	O
76	observed	O
76	in	O
76	41	O
76	%	O
76	of	O
76	analyzed	O
76	patients	O
76	,	O
76	t	O
76	(	O
76	4;14	O
76	)	O
76	in	O
76	14	O
76	%	O
76	of	O
76	patients	O
76	,	O
76	and	O
76	del(17p	O
76	)	O
76	in	O
76	7	O
76	%	O
76	of	O
76	patients	O
76	(	O
76	Table	O
76	1	O
76	)	O
76	,	O
76	in	O
76	agreement	O
76	with	O
76	earlier	O
76	reports	O
76	.	O
76	Patients	O
76	had	O
76	received	O
76	a	O
76	median	O
76	of	O
76	three	O
76	prior	O
76	therapies	O
76	(	O
76	range	O
76	,	O
76	1	O
76	-	O
76	10	O
76	)	O
76	;	O
76	86	O
76	%	O
76	of	O
76	patients	O
76	had	O
76	received	O
76	prior	O
76	thalidomide	O
76	therapy	O
76	and	O
76	81	O
76	%	O
76	had	O
76	received	O
76	prior	O
76	bortezomib	O
76	therapy	O
76	.	O
76	At	O
76	the	O
76	time	O
76	of	O
76	analysis	O
76	(	O
76	November	O
76	2007	O
76	)	O
76	,	O
76	all	O
76	patients	O
76	had	O
76	received	O
76	lenalidomide	O
76	plus	O
76	dexamethasone	O
76	for	O
76	a	O
76	median	O
76	of	O
76	five	O
76	cycles	O
76	(	O
76	range	O
76	,	O
76	1	O
76	-	O
76	22	O
76	)	O
76	(	O
76	Table	O
76	1	O
76	)	O
76	.	O
--------------------------------------------------------------
77	Among	O
77	the	O
77	207	O
77	patients	O
77	,	O
77	the	O
77	ORR	O
77	was	O
77	achieved	O
77	in	O
77	59	O
77	%	O
77	of	O
77	patients	O
77	,	O
77	including	O
77	complete	O
77	response	O
77	in	O
77	7	O
77	%	O
77	and	O
77	very	O
77	good	O
77	partial	O
77	response	O
77	in	O
77	14	O
77	%	O
77	.	O
77	The	O
77	median	B-arm_efficacy_metric
77	PFS	B-arm_efficacy_metric
77	was	O
77	9.6	B-arm_efficacy_results
77	months	B-arm_efficacy_results
77	and	O
77	the	O
77	median	O
77	OS	O
77	was	O
77	15.1	O
77	months	O
77	(	O
77	Table	O
77	2	O
77	)	O
77	.	O
--------------------------------------------------------------
78	Impact	O
78	of	O
78	chromosomal	O
78	abnormalities	O
78	.	O
78	Among	B-arm_description
78	patients	B-arm_description
78	with	B-arm_description
78	del(13	B-arm_description
78	)	B-arm_description
78	compared	O
78	with	O
78	patients	B-arm_description
78	without	B-arm_description
78	del(13	B-arm_description
78	)	B-arm_description
78	,	O
78	the	O
78	ORR	O
78	was	O
78	significantly	O
78	lower	O
78	,	O
78	and	O
78	median	O
78	PFS	O
78	and	O
78	OS	O
78	were	O
78	significantly	O
78	shorter	O
78	,	O
78	(	O
78	ORR	O
78	43	O
78	%	O
78	vs	O
78	71	O
78	%	O
78	,	O
78	respectively	O
78	,	O
78	Po0.001	O
78	;	O
78	median	B-arm_efficacy_metric
78	PFS	B-arm_efficacy_metric
78	5.0	B-arm_efficacy_results
78	months	B-arm_efficacy_results
78	vs	O
78	12.5	B-arm_efficacy_results
78	months	B-arm_efficacy_results
78	,	B-arm_efficacy_results
78	Po0.0001	B-arm_efficacy_results
78	;	O
78	median	O
78	OS	O
78	10.4	O
78	months	O
78	vs	O
78	17.4	O
78	months	O
78	,	O
78	P	O
78	¼	O
78	0.001	O
78	)	O
78	(	O
78	Table	O
78	2	O
78	;	O
78	Figures	O
78	1a	O
78	and	O
78	b	O
78	)	O
78	.	O
78	A	O
78	similar	O
78	pattern	O
78	was	O
78	observed	O
78	among	O
78	patients	B-arm_description
78	with	B-arm_description
78	t(4;14	B-arm_description
78	)	B-arm_description
78	compared	O
78	with	O
78	patients	B-arm_description
78	without	B-arm_description
78	t(4;14	B-arm_description
78	)	B-arm_description
78	(	O
78	ORR	O
78	39	O
78	%	O
78	vs	O
78	62	O
78	%	O
78	,	O
78	respectively	O
78	,	O
78	P	O
78	¼	O
78	0.04	O
78	;	O
78	median	B-arm_efficacy_metric
78	PFS	B-arm_efficacy_metric
78	5.5	B-arm_efficacy_results
78	months	B-arm_efficacy_results
78	vs	O
78	10.6	B-arm_efficacy_results
78	months	B-arm_efficacy_results
78	,	O
78	Po0.01	B-arm_efficacy_results
78	;	O
78	median	O
78	OS	O
78	9.4	O
78	months	O
78	vs	O
78	15.4	O
78	months	O
78	,	O
78	P	O
78	¼	O
78	0.005	O
78	)	O
78	(	O
78	Table	O
78	2	O
78	)	O
78	.	O
--------------------------------------------------------------
79	Patients	O
79	with	O
79	isolated	O
79	del(13	O
79	)	O
79	,	O
79	defined	O
79	as	O
79	the	O
79	presence	O
79	of	O
79	del(13	O
79	)	O
79	without	O
79	t	O
79	(	O
79	4;14	O
79	)	O
79	or	O
79	del(17p	O
79	)	O
79	,	O
79	had	O
79	significantly	O
79	lower	O
79	ORR	O
79	compared	O
79	with	O
79	patients	B-arm_description
79	without	B-arm_description
79	isolated	B-arm_description
79	del(13	B-arm_description
79	)	B-arm_description
79	(	O
79	43	O
79	%	O
79	vs	O
79	71	O
79	%	O
79	,	O
79	respectively	O
79	;	O
79	P	O
79	¼	O
79	0.01	O
79	)	O
79	(	O
79	Table	O
79	2	O
79	)	O
79	.	O
79	In	O
79	contrast	O
79	,	O
79	the	O
79	median	B-arm_efficacy_metric
79	PFS	B-arm_efficacy_metric
79	and	O
79	OS	O
79	were	O
79	not	O
79	(	O
79	or	O
79	marginally	O
79	)	O
79	shorter	O
79	in	O
79	patients	B-arm_description
79	with	B-arm_description
79	isolated	B-arm_description
79	del(13	B-arm_description
79	)	B-arm_description
79	(	O
79	PFS	O
79	was	O
79	8	B-arm_efficacy_results
79	months	B-arm_efficacy_results
79	vs	O
79	10.4	B-arm_efficacy_results
79	months	B-arm_efficacy_results
79	,	B-arm_efficacy_results
79	P	B-arm_efficacy_results
79	¼	B-arm_efficacy_results
79	0.05	B-arm_efficacy_results
79	;	O
79	OS	O
79	was	O
79	10.8	O
79	months	O
79	vs	O
79	15.1	O
79	months	O
79	,	O
79	P	O
79	¼	O
79	0.56	O
79	)	O
79	.	O
79	The	O
79	number	O
79	of	O
79	patients	O
79	with	O
79	del(17p	O
79	)	O
79	was	O
79	too	O
79	low	O
79	for	O
79	meaningful	O
79	interpretation	O
79	.	O
--------------------------------------------------------------
80	Impact	O
80	of	O
80	prior	O
80	treatment	O
80	.	O
80	Patients	B-arm_description
80	who	I-arm_description
80	had	I-arm_description
80	received	I-arm_description
80	prior	I-arm_description
80	treatment	I-arm_description
80	with	I-arm_description
80	bortezomib	I-arm_description
80	had	O
80	significantly	O
80	lower	O
80	ORR	O
80	(	O
80	55.4	O
80	%	O
80	vs	O
80	74.3	O
80	%	O
80	;	O
80	P	O
80	¼	O
80	0.04	O
80	)	O
80	,	O
80	shorter	O
80	median	B-arm_efficacy_metric
80	PFS	I-arm_efficacy_metric
80	(	O
80	8.3	B-arm_efficacy_results
80	months	B-arm_efficacy_results
80	vs	O
80	not	B-arm_efficacy_results
80	reached	I-arm_efficacy_results
80	;	I-arm_efficacy_results
80	P	I-arm_efficacy_results
80	¼	I-arm_efficacy_results
80	0.0003	I-arm_efficacy_results
80	)	O
80	and	O
80	significantly	O
80	shorter	O
80	median	O
80	OS	O
80	(	O
80	12.2	O
80	months	O
80	vs	O
80	not	O
80	reached	O
80	;	O
80	Po0.002	O
80	)	O
80	compared	O
80	with	O
80	patients	B-arm_description
80	who	I-arm_description
80	did	I-arm_description
80	not	I-arm_description
80	receive	I-arm_description
80	prior	I-arm_description
80	bortezomib	I-arm_description
80	.	O
80	In	O
80	contrast	O
80	,	O
80	patients	B-arm_description
80	who	I-arm_description
80	received	I-arm_description
80	prior	I-arm_description
80	thalidomide	I-arm_description
80	therapy	O
80	had	O
80	comparable	O
80	ORR	O
80	(	O
80	57.0	O
80	%	O
80	vs	O
80	69.2	O
80	%	O
80	;	O
80	P	O
80	¼	O
80	0.24	O
80	)	O
80	,	O
80	as	O
80	well	O
80	as	O
80	comparable	O
80	median	B-arm_efficacy_metric
80	PFS	B-arm_efficacy_metric
80	(	O
80	8.5	B-arm_efficacy_results
80	months	B-arm_efficacy_results
80	vs	O
80	10.6	B-arm_efficacy_results
80	months	B-arm_efficacy_results
80	;	B-arm_efficacy_results
80	P	B-arm_efficacy_results
80	¼	B-arm_efficacy_results
80	0.10	B-arm_efficacy_results
80	)	B-arm_efficacy_results
80	and	O
80	median	O
80	OS	O
80	,	O
80	and	O
80	del(17p	O
80	)	O
80	,	O
80	32	O
80	had	O
80	del(13	O
80	)	O
80	without	O
80	t	O
80	(	O
80	4;14	O
80	)	O
80	or	O
80	del(17p	O
80	)	O
80	.	O
--------------------------------------------------------------
81	(	O
81	9.4	O
81	months	O
81	vs	O
81	not	O
81	yet	O
81	reached	O
81	,	O
81	P	O
81	¼	O
81	0.43	O
81	)	O
81	compared	O
81	with	O
81	those	O
81	who	O
81	were	O
81	not	O
81	earlier	O
81	treated	O
81	with	O
81	thalidomide	O
81	.	O
81	Patients	B-arm_description
81	who	I-arm_description
81	progressed	I-arm_description
81	during	I-arm_description
81	thalidomide	I-arm_description
81	therapy	I-arm_description
81	had	O
81	a	O
81	significantly	O
81	shorter	O
81	PFS	B-arm_efficacy_metric
81	(	O
81	5.7	B-arm_efficacy_results
81	months	B-arm_efficacy_results
81	vs	O
81	15.7	B-arm_efficacy_results
81	months	B-arm_efficacy_results
81	;	B-arm_efficacy_results
81	Po0.0001	B-arm_efficacy_results
81	)	O
81	and	O
81	OS	O
81	(	O
81	9.7	O
81	months	O
81	vs	O
81	16.1	O
81	months	O
81	;	O
81	P	O
81	¼	O
81	0.0007	O
81	)	O
81	compared	O
81	with	O
81	those	B-arm_description
81	who	I-arm_description
81	did	I-arm_description
81	not	I-arm_description
81	progress	I-arm_description
81	during	I-arm_description
81	thalidomide	I-arm_description
81	therapy	I-arm_description
81	(	O
81	Figures	O
81	2a	O
81	and	O
81	b	O
81	)	O
81	.	O
81	Patients	O
81	who	O
81	were	O
81	thalidomide	O
81	resistant	O
81	had	O
81	received	O
81	an	O
81	additional	O
81	line	O
81	of	O
81	therapy	O
81	(	O
81	median	O
81	,	O
81	4	O
81	vs	O
81	3	O
81	)	O
81	and	O
81	a	O
81	higher	O
81	proportion	O
81	had	O
81	t(4;14	O
81	)	O
81	(	O
81	16	O
81	%	O
81	vs	O
81	9	O
81	%	O
81	)	O
81	compared	O
81	with	O
81	patients	O
81	who	O
81	were	O
81	not	O
81	thalidomide	O
81	resistant	O
81	.	O
--------------------------------------------------------------
82	Additional	O
82	analyses	O
82	were	O
82	conducted	O
82	to	O
82	determine	O
82	the	O
82	combined	O
82	impact	O
82	of	O
82	progression	O
82	on	O
82	thalidomide	O
82	and	O
82	either	O
82	del	O
82	(	O
82	13	O
82	)	O
82	or	O
82	prior	O
82	bortezomib	O
82	use	O
82	on	O
82	OS	O
82	.	O
82	For	O
82	patients	O
82	who	O
82	did	O
82	not	O
82	progress	O
82	on	O
82	thalidomide	O
82	,	O
82	the	O
82	median	O
82	OS	O
82	was	O
82	10.4	O
82	months	O
82	for	O
82	patients	O
82	with	O
82	del	O
82	(	O
82	13	O
82	)	O
82	and	O
82	not	O
82	reached	O
82	for	O
82	patients	O
82	without	O
82	del(13	O
82	)	O
82	.	O
82	However	O
82	,	O
82	for	O
82	patients	O
82	who	O
82	progressed	O
82	on	O
82	thalidomide	O
82	,	O
82	there	O
82	was	O
82	no	O
82	difference	O
82	in	O
82	OS	O
82	between	O
82	patients	O
82	with	O
82	or	O
82	without	O
82	del(13	O
82	)	O
82	(	O
82	median	O
82	9.5	O
82	months	O
82	vs	O
82	9.7	O
82	months	O
82	,	O
82	respectively	O
82	)	O
82	.	O
82	For	O
82	patients	O
82	who	O
82	progressed	O
82	on	O
82	thalidomide	O
82	,	O
82	the	O
82	median	O
82	OS	O
82	was	O
82	11.6	O
82	months	O
82	if	O
82	they	O
82	had	O
82	prior	O
82	bortezomib	O
82	and	O
82	not	O
82	reached	O
82	if	O
82	they	O
82	had	O
82	no	O
82	prior	O
82	bortezomib	O
82	.	O
82	However	O
82	,	O
82	for	O
82	patients	O
82	with	O
82	no	O
82	prior	O
82	bortezomib	O
82	use	O
82	,	O
82	there	O
82	was	O
82	no	O
82	difference	O
82	in	O
82	OS	O
82	between	O
82	patients	O
82	with	O
82	or	O
82	without	O
82	progression	O
82	on	O
82	thalidomide	O
82	(	O
82	median	O
82	not	O
82	reached	O
82	for	O
82	both	O
82	)	O
82	.	O
--------------------------------------------------------------
83	Multivariate	O
83	analysis	O
83	on	O
83	ORR	O
83	identified	O
83	lower	O
83	hemoglobin	O
83	level	O
83	o10	O
83	g	O
83	100	O
83	ml	O
83	(	O
83	hazard	O
83	ratio	O
83	(	O
83	HR	O
83	)	O
83	:	O
83	1.230	O
83	;	O
83	95	O
83	%	O
83	confidence	O
83	interval	O
83	(	O
83	CI	O
83	)	O
83	:	O
83	1.000	O
83	-	O
83	1.511	O
83	;	O
83	P	O
83	¼	O
83	0.05	O
83	)	O
83	,	O
83	increased	O
83	number	O
83	of	O
83	prior	O
83	therapies	O
83	(	O
83	HR	O
83	:	O
83	0.745	O
83	;	O
83	95	O
83	%	O
83	CI	O
83	:	O
83	0.573	O
83	-	O
83	0.967	O
83	;	O
83	P	O
83	¼	O
83	0.03	O
83	)	O
83	,	O
83	and	O
83	del(13	O
83	)	O
83	(	O
83	HR	O
83	:	O
83	3.431	O
83	;	O
83	95	O
83	%	O
83	CI	O
83	:	O
83	1.531	O
83	-	O
83	7.689	O
83	;	O
83	P	O
83	¼	O
83	0.003	O
83	)	O
83	as	O
83	independent	O
83	predictors	O
83	of	O
83	lower	O
83	ORR	O
83	(	O
83	Table	O
83	3	O
83	)	O
83	.	O
83	Sex	O
83	and	O
83	t(4;14	O
83	)	O
83	met	O
83	the	O
83	criteria	O
83	to	O
83	stay	O
83	in	O
83	the	O
83	model	O
83	though	O
83	they	O
83	were	O
83	not	O
83	statistically	O
83	significant	O
83	.	O
83	Age	O
83	,	O
83	sex	O
83	,	O
83	prior	O
83	transplant	O
83	,	O
83	prior	O
83	bortezomib	O
83	use	O
83	,	O
83	prior	O
83	thalidomide	O
83	use	O
83	,	O
83	and	O
83	progression	O
83	during	O
83	thalidomide	O
83	did	O
83	not	O
83	affect	O
83	ORR	O
83	(	O
83	Table	O
83	3	O
83	)	O
83	.	O
83	Multivariate	O
83	analysis	O
83	on	O
83	PFS	O
83	identified	O
83	progression	O
83	during	O
83	thalidomide	O
83	(	O
83	HR	O
83	:	O
83	2.72	O
83	;	O
83	95	O
83	%	O
83	CI	O
83	:	O
83	1.66	O
83	-	O
83	4.46	O
83	;	O
83	Po0.0001	O
83	)	O
83	,	O
83	del(13	O
83	)	O
83	(	O
83	HR	O
83	:	O
83	2.35	O
83	;	O
83	95	O
83	%	O
83	CI	O
83	:	O
83	1.44	O
83	-	O
83	3.83	O
83	;	O
83	Po0.001	O
83	)	O
83	,	O
83	and	O
83	lower	O
83	hemoglobin	O
83	level	O
83	o10	O
83	g	O
83	per	O
83	100	O
83	ml	O
83	(	O
83	HR	O
83	:	O
83	0.81	O
83	;	O
83	95	O
83	%	O
83	CI	O
83	:	O
83	0.71	O
83	-	O
83	0.93	O
83	;	O
83	P	O
83	¼	O
83	0.002	O
83	)	O
83	as	O
83	independent	O
83	predictors	O
83	of	O
83	reduced	O
83	PFS	O
83	(	O
83	Table	O
83	4	O
83	)	O
83	.	O
83	There	O
83	was	O
83	a	O
83	trend	O
83	toward	O
83	reduced	O
83	PFS	O
83	with	O
83	prior	O
83	bortezomib	O
83	use	O
83	(	O
83	HR	O
83	:	O
83	2.37	O
83	;	O
83	95	O
83	%	O
83	CI	O
83	:	O
83	0.91	O
83	-	O
83	6.16	O
83	;	O
83	P	O
83	¼	O
83	0.076	O
83	)	O
83	and	O
83	increased	O
83	number	O
83	of	O
83	prior	O
83	therapies	O
83	(	O
83	HR	O
83	:	O
83	1.17	O
83	.	O
83	95	O
83	%	O
83	CI	O
83	:	O
83	0.99	O
83	-	O
83	1.37	O
83	;	O
83	P	O
83	¼	O
83	0.062	O
83	)	O
83	(	O
83	Table	O
83	4	O
83	)	O
83	.	O
83	Age	O
83	,	O
83	sex	O
83	,	O
83	prior	O
83	transplant	O
83	,	O
83	prior	O
83	thalidomide	O
83	use	O
83	,	O
83	and	O
83	t(4;14	O
83	)	O
83	translocation	O
83	were	O
83	not	O
83	predictive	O
83	of	O
83	PFS	O
83	(	O
83	Table	O
83	4	O
83	)	O
83	.	O
--------------------------------------------------------------
84	Multivariate	O
84	analysis	O
84	on	O
84	OS	O
84	identified	O
84	progression	O
84	on	O
84	thalidomide	O
84	(	O
84	HR	O
84	:	O
84	1.810	O
84	;	O
84	95	O
84	%	O
84	CI	O
84	:	O
84	1.081	O
84	-	O
84	3.030	O
84	;	O
84	Po0.02	O
84	)	O
84	as	O
84	the	O
84	only	O
84	significant	O
84	independent	O
84	predictor	O
84	of	O
84	reduced	O
84	OS	O
84	(	O
84	Table	O
84	5	O
84	)	O
84	.	O
84	There	O
84	was	O
84	a	O
84	trend	O
84	toward	O
84	reduced	O
84	OS	O
84	with	O
84	prior	O
84	bortezomib	O
84	use	O
84	(	O
84	HR	O
84	:	O
84	2.611	O
84	;	O
84	95	O
84	%	O
84	CI	O
84	:	O
84	0.927	O
84	-	O
84	7.360	O
84	;	O
84	P	O
84	¼	O
84	0.07	O
84	)	O
84	(	O
84	Table	O
84	5	O
84	)	O
84	.	O
84	Del(13	O
84	)	O
84	and	O
84	t(4;14	O
84	)	O
84	met	O
84	the	O
84	criteria	O
84	to	O
84	stay	O
84	in	O
84	the	O
84	model	O
84	though	O
84	they	O
84	were	O
84	not	O
84	statistically	O
84	significant	O
84	.	O
84	Age	O
84	,	O
84	sex	O
84	,	O
84	number	O
84	of	O
84	lines	O
84	of	O
84	prior	O
84	therapy	O
84	,	O
84	prior	O
84	transplant	O
84	,	O
84	prior	O
84	thalidomide	O
84	treatment	O
84	,	O
84	and	O
84	hemoglobin	O
84	level	O
84	did	O
84	not	O
84	affect	O
84	OS	O
84	(	O
84	Table	O
84	5	O
84	)	O
84	.	O
--------------------------------------------------------------
85	Randomized	B-study_type
85	Phase	B-study_type
85	II	B-study_type
85	Trial	B-study_type
85	of	O
85	Thalidomide	B-arm_description
85	Alone	B-arm_description
85	versus	O
85	Thalidomide	B-arm_description
85	Plus	B-arm_description
85	Interferon	B-arm_description
85	Alpha	B-arm_description
85	in	O
85	Patients	O
85	with	O
85	Refractory	O
85	Multiple	O
85	Myeloma	O
85	Randomized	O
85	Phase	O
85	II	O
85	Trial	O
85	of	O
85	Thalidomide	O
85	Alone	O
85	versus	O
85	Thalidomide	O
85	Plus	O
85	Interferon	O
85	Alpha	O
85	in	O
85	Patients	O
85	with	O
85	Refractory	O
85	Multiple	O
85	Myeloma	O
85	M.D.Tzeon	O
85	-	O
85	JyeChiou	B-authors
--------------------------------------------------------------
86	National	O
86	Cheng	O
86	Kung	O
86	University	O
86	Hospital	O
86	Tainan	O
86	Taiwan	O
86	M.DTsai	B-authors
86	-	O
86	YunChen	B-authors
86	Mackay	O
86	Memorial	O
86	Hospital	O
86	Taipei	O
86	Taiwan	O
86	M.DMing	B-authors
86	-	B-authors
86	ChihChang	B-authors
86	Pingtung	O
86	Christian	O
86	Hospital	O
86	Pingtung	O
86	Taiwan	O
86	M.DErh	B-authors
86	-	B-authors
86	JungHsueh	B-authors
--------------------------------------------------------------
87	Randomized	B-study_type
87	Phase	B-study_type
87	II	B-study_type
87	Trial	B-study_type
87	of	O
87	Thalidomide	B-arm_description
87	Alone	B-arm_description
87	versus	O
87	Thalidomide	B-arm_description
87	Plus	B-arm_description
87	Interferon	B-arm_description
87	Alpha	B-arm_description
87	in	O
87	Patients	O
87	with	O
87	Refractory	O
87	Multiple	O
87	Myeloma	O
87	M.D.Tzeon	B-authors
87	-	B-authors
87	JyeChiou	B-authors
87	tjchiou@vghtpe.gov.tw	O
87	National	O
87	Taiwan	O
87	University	O
87	Taipei	O
--------------------------------------------------------------
88	Taiwan	O
88	Section	O
88	of	O
88	Medical	O
88	Oncology	O
88	Department	O
88	of	O
88	Medicine	O
88	Taipei	O
88	Veterans	O
88	General	O
88	Hospital	O
88	No	O
88	.	O
88	201	O
88	Sec	O
88	.	O
88	2	O
88	,	O
88	Shih	O
88	-	O
88	Pai	O
88	Road	O
88	112	O
88	Taipei	O
--------------------------------------------------------------
89	Taiwan	O
89	Taipei	O
89	Taiwan	O
89	Randomized	B-study_type
89	Phase	B-study_type
89	II	B-study_type
89	Trial	B-study_type
89	of	O
89	Thalidomide	B-arm_description
89	Alone	B-arm_description
89	versus	O
89	Thalidomide	B-arm_description
89	Plus	B-arm_description
89	Interferon	B-arm_description
89	Alpha	B-arm_description
89	in	O
89	Patients	O
89	with	O
89	Refractory	O
89	Multiple	O
89	Myeloma	O
89	0735	O
89	-	O
89	7907	O
89	print	O
89	/	O
89	1532	O
89	-	O
89	4192	O
89	0735	O
89	-	O
89	7907	O
89	print	O
89	/	O
89	1532	O
89	-	O
89	4192	O
89	10.1080/07357900701208808	O
--------------------------------------------------------------
90	Multiple	O
90	myeloma	O
90	(	O
90	MM	O
90	)	O
90	is	O
90	a	O
90	malignant	O
90	disease	O
90	of	O
90	the	O
90	plasma	O
90	cells	O
90	.	O
90	As	O
90	the	O
90	disease	O
90	progressing	O
90	,	O
90	it	O
90	will	O
90	destroy	O
90	normal	O
90	bone	O
90	tissue	O
90	,	O
90	causing	O
90	pain	O
90	and	O
90	crowding	O
90	normal	O
90	hematopoiesis	O
90	out	O
90	(	O
90	1)(2)(3)(4)(5	O
90	)	O
90	.	O
90	The	O
90	low	O
90	incidence	O
90	of	O
90	complete	O
90	remission	O
90	,	O
90	on	O
90	the	O
90	order	O
90	of	O
90	5	O
90	percent	O
90	,	O
90	reflects	O
90	the	O
90	marked	O
90	drug	O
90	resistance	O
90	of	O
90	myeloma	O
90	cells	O
90	.	O
90	Therapeutic	O
90	intervention	O
90	with	O
90	cytokines	O
90	is	O
90	being	O
90	evaluated	O
90	in	O
90	the	O
90	management	O
90	of	O
90	a	O
90	range	O
90	of	O
90	malignancies	O
90	.	O
90	Interferons	O
90	have	O
90	a	O
90	broad	O
90	spectrum	O
90	of	O
90	action	O
90	on	O
90	cellular	O
90	proliferation	O
90	as	O
90	well	O
90	as	O
90	immunomodulation	O
90	.	O
90	In	O
90	patients	O
90	with	O
90	myeloma	O
90	,	O
90	interferon	O
90	alpha	O
90	in	O
90	combination	O
90	with	O
90	chemotherapy	O
90	has	O
90	been	O
90	demonstrated	O
90	to	O
90	have	O
90	synergistic	O
90	anti	O
90	-	O
90	tumor	O
90	effect	O
90	(	O
90	1)(2)(3)(4)(5	O
90	)	O
90	.	O
90	Response	O
90	rates	O
90	of	O
90	20	O
90	percent	O
90	were	O
90	achieved	O
90	when	O
90	interferon	O
90	alpha	O
90	(	O
90	IFN	O
90	-	O
90	α	O
90	)	O
90	was	O
90	applied	O
90	as	O
90	single	O
90	agent	O
90	for	O
90	multiple	O
90	myeloma	O
90	(	O
90	6	O
90	)	O
90	.	O
90	A	O
90	synergistic	O
90	activity	O
90	was	O
90	observed	O
90	when	O
90	IFN	O
90	-	O
90	α	O
90	was	O
90	combined	O
90	with	O
90	chemotherapeutic	O
90	agents	O
90	in	O
90	vitro	O
90	and	O
90	in	O
90	vivo	O
90	,	O
90	resulted	O
90	in	O
90	higher	O
90	median	O
90	progression	O
90	-	O
90	free	O
90	and	O
90	overall	O
90	survival	O
90	duration	O
90	in	O
90	the	O
90	VAD	O
90	(	O
90	Vincristin	O
90	,	O
90	Adriamycin	O
90	,	O
90	Dexamethasone	O
90	)	O
90	and	O
90	IFN	O
90	-	O
90	α	O
90	combination	O
90	(	O
90	7	O
90	)	O
90	.	O
--------------------------------------------------------------
91	Thalidomide	O
91	(	O
91	TD	O
91	)	O
91	was	O
91	used	O
91	during	O
91	the	O
91	late	O
91	1950s	O
91	and	O
91	withdrawn	O
91	in	O
91	the	O
91	1960s	O
91	after	O
91	the	O
91	appearance	O
91	of	O
91	teratogenicity	O
91	and	O
91	phocomelia	O
91	.	O
91	The	O
91	recent	O
91	return	O
91	of	O
91	thalidomide	O
91	stems	O
91	from	O
91	the	O
91	broad	O
91	spectrum	O
91	of	O
91	its	O
91	potential	O
91	pharmacologic	O
91	and	O
91	immunologic	O
91	effects	O
91	(	O
91	8)(9)(10	O
91	)	O
91	.	O
91	The	O
91	mechanism	O
91	of	O
91	thalidomide	O
91	in	O
91	treating	O
91	multiple	O
91	myeloma	O
91	includes	O
91	the	O
91	possibility	O
91	that	O
91	thalidomide	O
91	suppresses	O
91	tumor	O
91	necrosis	O
91	factor	O
91	-	O
91	α	O
91	production	O
91	,	O
91	increases	O
91	the	O
91	body	O
91	's	O
91	production	O
91	of	O
91	interluekin-10	O
91	(	O
91	IL-10	O
91	)	O
91	,	O
91	and	O
91	inhibits	O
91	angiogenesis	O
91	by	O
91	preventing	O
91	the	O
91	growth	O
91	of	O
91	new	O
91	blood	O
91	vessels	O
91	to	O
91	support	O
91	the	O
91	malignant	O
91	cells	O
91	(	O
91	10,11	O
91	)	O
91	.	O
91	The	O
91	combination	O
91	of	O
91	IFN	O
91	-	O
91	alpha2b	O
91	and	O
91	thalidomide	O
91	had	O
91	been	O
91	reported	O
91	to	O
91	cause	O
91	synergistic	O
91	decrease	O
91	in	O
91	mean	O
91	vessel	O
91	count	O
91	in	O
91	tumors	O
91	that	O
91	were	O
91	resistant	O
91	to	O
91	the	O
91	antiproliferative	O
91	effects	O
91	of	O
91	IFN	O
91	-	O
91	alpha2b	O
91	and	O
91	thalidomide	O
91	in	O
91	vitro	O
91	and	O
91	have	O
91	potentiated	O
91	antiangiogenic	O
91	activity	O
91	in	O
91	a	O
91	xenograft	O
91	model	O
91	(	O
91	12	O
91	)	O
91	.	O
91	Whether	O
91	the	O
91	combination	O
91	of	O
91	IFN	O
91	-	O
91	α	O
91	with	O
91	thalidomide	O
91	in	O
91	patients	O
91	who	O
91	did	O
91	not	O
91	receive	O
91	IFN	O
91	-	O
91	α	O
91	or	O
91	thalidomide	O
91	to	O
91	treat	O
91	their	O
91	disease	O
91	before	O
91	can	O
91	improve	O
91	the	O
91	response	O
91	rate	O
91	,	O
91	duration	O
91	,	O
91	and	O
91	survival	O
91	were	O
91	interesting	O
91	to	O
91	us	O
91	.	O
91	In	O
91	this	O
91	study	O
91	,	O
91	we	O
91	will	O
91	evaluate	O
91	and	O
91	compare	O
91	the	O
91	efficacy	O
91	and	O
91	toxicity	O
91	of	O
91	thalidomide	B-arm_description
91	alone	B-arm_description
91	or	O
91	combined	B-arm_description
91	with	B-arm_description
91	IFN	B-arm_description
91	-	B-arm_description
91	α	B-arm_description
91	in	O
91	refractory	O
91	MM	O
91	patients	O
91	.	O
--------------------------------------------------------------
92	Patients	O
92	who	O
92	fulfill	O
92	the	O
92	following	O
92	criteria	O
92	were	O
92	enrolled	O
92	in	O
92	the	O
92	study	O
92	:	O
92	age	O
92	less	O
92	than	O
92	75-year	O
92	-	O
92	old	O
92	with	O
92	well	O
92	-	O
92	documented	O
92	multiple	O
92	myeloma	O
92	(	O
92	Durie	O
92	-	O
92	Salmon	O
92	staging	O
92	,	O
92	1976	O
92	)	O
92	that	O
92	relapsed	O
92	or	O
92	failed	O
92	to	O
92	first	O
92	-	O
92	line	O
92	chemotherapy	O
92	and	O
92	had	O
92	measurable	O
92	M	O
92	protein	O
92	and	O
92	paraprotein	O
92	serum	O
92	levels	O
92	;	O
92	no	O
92	history	O
92	of	O
92	exposure	O
92	to	O
92	IFN	O
92	-	O
92	α	O
92	or	O
92	thalidomide	O
92	before	O
92	;	O
92	ECOG	O
92	performance	O
92	status	O
92	≤2	O
92	with	O
92	adequate	O
92	liver	O
92	,	O
92	renal	O
92	function	O
92	,	O
92	and	O
92	hemogram	O
92	level	O
92	(	O
92	ALT	O
92	/	O
92	AST	O
92	≤3	O
92	times	O
92	upper	O
92	limit	O
92	of	O
92	normal	O
92	,	O
92	total	O
92	bilirubin	O
92	≤2	O
92	mg	O
92	percent	O
92	,	O
92	serum	O
92	creatinine	O
92	≤	O
92	2	O
92	times	O
92	normal	O
92	limit	O
92	,	O
92	Hemoglobin	O
92	>	O
92	8	O
92	g	O
92	/	O
92	dL	O
92	,	O
92	WBC	O
92	>	O
92	3000	O
92	/	O
92	mm	O
92	3	O
92	,	O
92	Platelet	O
92	>	O
92	7.5	O
92	×	O
92	10	O
92	4	O
92	/mm	O
92	3	O
92	)	O
92	;	O
92	no	O
92	history	O
92	of	O
92	nerve	O
92	damage	O
92	(	O
92	WHO	O
92	≥2	O
92	)	O
92	,	O
92	orthostatic	O
92	hypotension	O
92	,	O
92	or	O
92	other	O
92	serious	O
92	complications	O
92	;	O
92	at	O
92	least	O
92	3	O
92	weeks	O
92	interval	O
92	from	O
92	prior	O
92	chemotherapy	O
92	or	O
92	radiotherapy	O
92	and	O
92	signing	O
92	the	O
92	consent	O
92	form	O
92	prior	O
92	to	O
92	this	O
92	study	O
92	.	O
--------------------------------------------------------------
93	Based	O
93	on	O
93	previous	O
93	clinic	O
93	experience	O
93	,	O
93	a	O
93	response	O
93	rate	O
93	of	O
93	approximately	O
93	20	O
93	percent	O
93	was	O
93	assumed	O
93	for	O
93	the	O
93	study	O
93	regimen	O
93	with	O
93	thalidomide	O
93	and	O
93	an	O
93	estimated	O
93	response	O
93	rate	O
93	of	O
93	40	O
93	percent	O
93	was	O
93	assumed	O
93	for	O
93	the	O
93	study	O
93	regimen	O
93	with	O
93	thalidomide	O
93	plus	O
93	IFN	O
93	-	O
93	α	O
93	.	O
--------------------------------------------------------------
94	Simon	O
94	's	O
94	2-stage	O
94	optimal	O
94	design	O
94	was	O
94	adapted	O
94	to	O
94	calculate	O
94	the	O
94	sample	O
94	size	O
94	for	O
94	type	O
94	-	O
94	I	O
94	error	O
94	of	O
94	0.05	O
94	and	O
94	power	O
94	of	O
94	80	O
94	percent	O
94	.	O
--------------------------------------------------------------
95	The	O
95	sample	O
95	size	O
95	initially	O
95	was	O
95	determined	O
95	to	O
95	complete	O
95	43	O
95	evaluable	O
95	patients	O
95	for	O
95	the	O
95	regimen	O
95	with	O
95	thalidomide	B-arm_description
95	plus	B-arm_description
95	IFNα	B-arm_description
95	and	O
95	29	O
95	evaluable	O
95	patients	O
95	for	O
95	the	O
95	regimen	O
95	with	O
95	thalidomide	B-arm_description
95	alone	B-arm_description
95	.	O
95	The	O
95	study	O
95	was	O
95	approved	O
95	by	O
95	the	O
95	Joint	O
95	Institutional	O
95	Review	O
95	Boards	O
95	in	O
95	Taiwan	O
95	;	O
95	it	O
95	started	O
95	in	O
95	March	O
95	2001	O
95	and	O
95	early	O
95	terminated	O
95	in	O
95	January	O
95	2004	O
95	due	O
95	to	O
95	the	O
95	interim	O
95	analysis	O
95	resulting	O
95	in	O
95	more	O
95	adverse	O
95	effects	O
95	and	O
95	less	O
95	efficacy	O
95	in	O
95	the	O
95	arm	O
95	A.	O
--------------------------------------------------------------
96	This	O
96	was	O
96	an	O
96	open	B-study_type
96	-	B-study_type
96	label	I-study_type
96	,	I-study_type
96	randomized	I-study_type
96	,	I-study_type
96	multicenter	I-study_type
96	Phase	I-study_type
96	II	I-study_type
96	clinical	I-study_type
96	trial	I-study_type
96	.	O
96	Patients	O
96	were	O
96	randomized	O
96	to	O
96	receive	O
96	either	O
96	thalidomide	B-arm_dosage
96	alone	I-arm_dosage
96	(	I-arm_dosage
96	200	B-arm_dosage
96	mg	I-arm_dosage
96	/	I-arm_dosage
96	day	I-arm_dosage
96	up	I-arm_dosage
96	to	I-arm_dosage
96	the	I-arm_dosage
96	maximum	I-arm_dosage
96	dose	I-arm_dosage
96	800	I-arm_dosage
96	mg	I-arm_dosage
96	/	I-arm_dosage
96	day	I-arm_dosage
96	,	B-arm_description
96	arm	I-arm_description
96	B	I-arm_description
96	)	O
96	or	O
96	the	O
96	combination	O
96	of	O
96	thalidomide	B-arm_dosage
96	and	B-arm_dosage
96	IFN	I-arm_dosage
96	-	I-arm_dosage
96	α	I-arm_dosage
96	(	I-arm_dosage
96	3	I-arm_dosage
96	MIU	I-arm_dosage
96	/	I-arm_dosage
96	m	I-arm_dosage
96	2	I-arm_dosage
96	subcutaneous	I-arm_dosage
96	injection	I-arm_dosage
96	thrice	I-arm_dosage
96	weekly	I-arm_dosage
96	,	B-arm_description
96	arm	B-arm_description
96	A	B-arm_description
96	)	O
96	.	O
96	The	O
96	randomization	O
96	list	O
96	was	O
96	generated	O
96	by	O
96	computer	O
96	using	O
96	permuted	O
96	-	O
96	block	O
96	randomization	O
96	with	O
96	a	O
96	block	O
96	size	O
96	of	O
96	5	O
96	patients	O
96	including	O
96	3	O
96	for	O
96	arm	O
96	A	O
96	and	O
96	the	O
96	other	O
96	2	O
96	for	O
96	arm	O
96	B.	O
96	Eligible	O
96	patients	O
96	recruited	O
96	from	O
96	7	O
96	medical	O
96	centers	O
96	around	O
96	Taiwan	O
96	were	O
96	registered	O
96	within	O
96	48	O
96	hours	O
96	before	O
96	the	O
96	initiation	O
96	of	O
96	therapy	O
96	.	O
96	Patients	O
96	were	O
96	then	O
96	assigned	O
96	to	O
96	either	O
96	arm	O
96	A	O
96	or	O
96	arm	O
96	B	O
96	by	O
96	an	O
96	independent	O
96	allocation	O
96	center	O
96	according	O
96	to	O
96	the	O
96	randomization	O
96	scheme	O
96	once	O
96	upon	O
96	registered	O
96	.	O
96	The	O
96	flow	O
96	diagram	O
96	of	O
96	the	O
96	progress	O
96	through	O
96	the	O
96	trial	O
96	was	O
96	shown	O
96	in	O
96	Figure	O
96	1	O
96	.	O
--------------------------------------------------------------
97	Thalidomide	B-arm_dosage
97	(	I-arm_dosage
97	50-mg	I-arm_dosage
97	capsules	I-arm_dosage
97	)	I-arm_dosage
97	(	I-arm_dosage
97	Thado	I-arm_dosage
97	,	I-arm_dosage
97	TTY	I-arm_dosage
97	Biopharm	I-arm_dosage
97	Co.	I-arm_dosage
97	,	I-arm_dosage
97	Taiwan	I-arm_dosage
97	,	I-arm_dosage
97	R.O.C.	I-arm_dosage
97	)	I-arm_dosage
97	was	I-arm_dosage
97	administered	I-arm_dosage
97	at	I-arm_dosage
97	a	I-arm_dosage
97	dose	I-arm_dosage
97	of	I-arm_dosage
97	200	I-arm_dosage
97	mg	I-arm_dosage
97	per	I-arm_dosage
97	day	I-arm_dosage
97	orally	I-arm_dosage
97	and	I-arm_dosage
97	divided	I-arm_dosage
97	into	I-arm_dosage
97	2	I-arm_dosage
97	times	I-arm_dosage
97	a	I-arm_dosage
97	day	I-arm_dosage
97	.	I-arm_dosage
97	The	I-arm_dosage
97	dose	I-arm_dosage
97	of	I-arm_dosage
97	thalidomide	I-arm_dosage
97	was	I-arm_dosage
97	increased	I-arm_dosage
97	by	I-arm_dosage
97	200	I-arm_dosage
97	mg	I-arm_dosage
97	every	I-arm_dosage
97	2	I-arm_dosage
97	weeks	I-arm_dosage
97	in	I-arm_dosage
97	the	I-arm_dosage
97	absence	I-arm_dosage
97	of	I-arm_dosage
97	intolerable	I-arm_dosage
97	adverse	I-arm_dosage
97	effects	I-arm_dosage
97	,	I-arm_dosage
97	to	I-arm_dosage
97	the	I-arm_dosage
97	maximal	I-arm_dosage
97	daily	I-arm_dosage
97	dose	I-arm_dosage
97	of	I-arm_dosage
97	800	I-arm_dosage
97	mg	I-arm_dosage
97	.	O
97	Patients	B-arm_dosage
97	who	I-arm_dosage
97	were	I-arm_dosage
97	allocated	I-arm_dosage
97	to	I-arm_dosage
97	arm	I-arm_dosage
97	A	I-arm_dosage
97	also	I-arm_dosage
97	received	I-arm_dosage
97	3	I-arm_dosage
97	MIU	I-arm_dosage
97	/	I-arm_dosage
97	m	I-arm_dosage
97	2	I-arm_dosage
97	of	I-arm_dosage
97	interferon	I-arm_dosage
97	alpha-2b	I-arm_dosage
97	(	I-arm_dosage
97	Schering	I-arm_dosage
97	-	I-arm_dosage
97	Plough	I-arm_dosage
97	Limited	I-arm_dosage
97	Co.	I-arm_dosage
97	,	I-arm_dosage
97	Schering	I-arm_dosage
97	-	I-arm_dosage
97	Plough	I-arm_dosage
97	Labo	I-arm_dosage
97	,	I-arm_dosage
97	N.V.	I-arm_dosage
97	)	I-arm_dosage
97	subcutaneous	I-arm_dosage
97	injection	I-arm_dosage
97	3	I-arm_dosage
97	times	I-arm_dosage
97	weekly	I-arm_dosage
97	concomitantly	I-arm_dosage
97	.	O
--------------------------------------------------------------
98	The	O
98	primary	O
98	end	O
98	point	O
98	of	O
98	the	O
98	study	O
98	was	O
98	to	O
98	determine	O
98	the	O
98	decline	O
98	in	O
98	the	O
98	level	O
98	of	O
98	paraprotein	O
98	in	O
98	serum	O
98	at	O
98	least	O
98	25	O
98	,	O
98	50	O
98	,	O
98	75	O
98	,	O
98	or	O
98	90	O
98	percernt	O
98	on	O
98	2	O
98	occasions	O
98	at	O
98	least	O
98	4	O
98	weeks	O
98	apart	O
98	.	O
98	The	O
98	response	O
98	was	O
98	evaluated	O
98	according	O
98	to	O
98	the	O
98	criteria	O
98	of	O
98	Cooper	O
98	et	O
98	al	O
98	.	O
98	and	O
98	Osterborg	O
98	et	O
98	al	O
98	.	O
98	(	O
98	2,3	O
98	)	O
98	.	O
98	Time	O
98	-	O
98	to	O
98	-	O
98	response	O
98	was	O
98	defined	O
98	as	O
98	the	O
98	interval	O
98	between	O
98	the	O
98	start	O
98	of	O
98	therapy	O
98	and	O
98	response	O
98	.	O
98	The	O
98	time	O
98	-	O
98	toprogression	O
98	was	O
98	calculated	O
98	only	O
98	for	O
98	patients	O
98	with	O
98	a	O
98	paraprotein	O
98	response	O
98	and	O
98	was	O
98	defined	O
98	as	O
98	the	O
98	time	O
98	from	O
98	the	O
98	start	O
98	of	O
98	therapy	O
98	to	O
98	disease	O
98	progression	O
98	.	O
98	Event	O
98	-	O
98	free	O
98	survival	O
98	was	O
98	calculated	O
98	from	O
98	the	O
98	start	O
98	of	O
98	therapy	O
98	to	O
98	disease	O
98	progression	O
98	,	O
98	removal	O
98	from	O
98	the	O
98	study	O
98	for	O
98	any	O
98	reason	O
98	,	O
98	death	O
98	from	O
98	any	O
98	cause	O
98	,	O
98	or	O
98	the	O
98	last	O
98	follow	O
98	-	O
98	up	O
98	visit	O
98	.	O
--------------------------------------------------------------
99	The	O
99	demographic	O
99	and	O
99	baseline	O
99	characteristics	O
99	,	O
99	comparison	O
99	of	O
99	continuous	O
99	variables	O
99	of	O
99	age	O
99	,	O
99	baseline	O
99	M	O
99	protein	O
99	levels	O
99	,	O
99	mean	O
99	treatment	O
99	duration	O
99	,	O
99	and	O
99	mean	O
99	total	O
99	thalidomide	O
99	used	O
99	dose	O
99	between	O
99	two	O
99	arms	O
99	were	O
99	determined	O
99	by	O
99	the	O
99	student	O
99	's	O
99	t	O
99	-	O
99	test	O
99	.	O
99	The	O
99	gender	O
99	,	O
99	immunophenotype	O
99	,	O
99	and	O
99	previous	O
99	treatments	O
99	were	O
99	summarized	O
99	as	O
99	categorical	O
99	parameters	O
99	and	O
99	were	O
99	assessed	O
99	with	O
99	the	O
99	use	O
99	of	O
99	chi	O
99	-	O
99	square	O
99	test	O
99	.	O
99	Analyses	O
99	for	O
99	the	O
99	efficacy	O
99	variables	O
99	and	O
99	safety	O
99	analysis	O
99	were	O
99	conducted	O
99	on	O
99	an	O
99	intention	O
99	-	O
99	to	O
99	-	O
99	treat	O
99	basis	O
99	.	O
99	The	O
99	primary	O
99	efficacy	O
99	analysis	O
99	was	O
99	in	O
99	descriptive	O
99	statistics	O
99	,	O
99	presented	O
99	by	O
99	point	O
99	estimate	O
99	and	O
99	95	O
99	percent	O
99	confidence	O
99	interval	O
99	for	O
99	the	O
99	primary	O
99	efficacy	O
99	variable	O
99	.	O
99	Comparison	O
99	of	O
99	the	O
99	response	O
99	according	O
99	to	O
99	the	O
99	response	O
99	criteria	O
99	was	O
99	assessed	O
99	with	O
99	the	O
99	use	O
99	of	O
99	the	O
99	chi	O
99	-	O
99	square	O
99	test	O
99	.	O
99	Ninetyfive	O
99	percent	O
99	confidence	O
99	intervals	O
99	(	O
99	95%CIs	O
99	)	O
99	for	O
99	the	O
99	confirmed	O
99	response	O
99	probability	O
99	were	O
99	calculated	O
99	using	O
99	binomial	O
99	95%CIs	O
99	.	O
99	Toxicity	O
99	incidence	O
99	was	O
99	estimated	O
99	and	O
99	summarized	O
99	using	O
99	fre	O
99	-	O
99	quency	O
99	and	O
99	descriptive	O
99	techniques	O
99	to	O
99	assess	O
99	any	O
99	patterns	O
99	.	O
99	Survival	O
99	distributions	O
99	(	O
99	Kaplan	O
99	-	O
99	Meier	O
99	)	O
99	of	O
99	event	O
99	-	O
99	free	O
99	survival	O
99	(	O
99	EFS	O
99	)	O
99	and	O
99	overall	O
99	survival	O
99	(	O
99	OS	O
99	)	O
99	were	O
99	compared	O
99	by	O
99	means	O
99	of	O
99	the	O
99	logrank	O
99	test	O
99	.	O
99	The	O
99	statistical	O
99	evaluation	O
99	was	O
99	conducted	O
99	by	O
99	the	O
99	software	O
99	program	O
99	of	O
99	SPSS	O
99	version	O
99	10.0	O
99	(	O
99	SPSS	O
99	Inc.	O
99	,	O
99	Chicago	O
99	,	O
99	IL	O
99	,	O
99	USA	O
99	)	O
99	.	O
99	All	O
99	patients	O
99	were	O
99	not	O
99	cohort	O
99	comparable	O
99	to	O
99	their	O
99	disease	O
99	duration	O
99	and	O
99	refractoriness	O
99	.	O
99	The	O
99	preparation	O
99	of	O
99	the	O
99	reports	O
99	after	O
99	early	O
99	terminating	O
99	this	O
99	trial	O
99	was	O
99	modified	O
99	from	O
99	the	O
99	CONSORT	O
99	Statement	O
99	(	O
99	13,14	O
99	)	O
99	.	O
--------------------------------------------------------------
100	From	O
100	March	O
100	2001	O
100	to	O
100	January	O
100	2004	O
100	,	O
100	28	O
100	patients	O
100	with	O
100	MM	O
100	whose	O
100	disease	O
100	relapsed	O
100	or	O
100	failed	O
100	to	O
100	first	O
100	-	O
100	line	O
100	chemotherapy	O
100	were	O
100	enrolled	O
100	in	O
100	this	O
100	study	O
100	.	O
100	Twelve	O
100	of	O
100	28	O
100	patients	O
100	were	O
100	randomized	B-study_type
100	to	O
100	receive	O
100	thalidomide	B-arm_description
100	alone	B-arm_description
100	(	B-arm_description
100	arm	B-arm_description
100	B	B-arm_description
100	)	B-arm_description
100	,	O
100	and	O
100	16	O
100	received	O
100	thalidomide	B-arm_description
100	combined	B-arm_description
100	with	B-arm_description
100	interferon	B-arm_dosage
100	alpha	I-arm_dosage
100	(	I-arm_dosage
100	3	I-arm_dosage
100	MIU	I-arm_dosage
100	/	I-arm_dosage
100	m	I-arm_dosage
100	2	I-arm_dosage
100	subcutaneous	I-arm_dosage
100	injection	I-arm_dosage
100	3	I-arm_dosage
100	times	I-arm_dosage
100	weekly	I-arm_dosage
100	,	B-arm_description
100	arm	B-arm_description
100	A	B-arm_description
100	)	O
100	.	O
100	No	O
100	obvious	O
100	differences	O
100	of	O
100	patients	O
100	'	O
100	characteristics	O
100	were	O
100	found	O
100	between	O
100	arm	O
100	B	O
100	and	O
100	arm	O
100	A.	O
100	The	O
100	median	O
100	cumulative	O
100	dose	O
100	of	O
100	interferon	O
100	was	O
100	31	O
100	MIU	O
100	/	O
100	m2	O
100	(	O
100	ranged	O
100	,	O
100	5	O
100	-	O
100	163	O
100	MIU	O
100	/	O
100	m2	O
100	)	O
100	in	O
100	arm	O
100	A.	O
100	However	O
100	,	O
100	the	O
100	average	O
100	treatmentduration	O
100	was	O
100	significantly	O
100	longer	O
100	in	O
100	arm	O
100	B	O
100	than	O
100	arm	O
100	A	O
100	(	O
100	236	O
100	days	O
100	versus	O
100	101	O
100	days	O
100	,	O
100	p	O
100	=	O
100	0.029	O
100	)	O
100	.	O
100	The	O
100	total	O
100	dose	O
100	of	O
100	thalidomide	O
100	in	O
100	B	O
100	arm	O
100	was	O
100	also	O
100	higher	O
100	(	O
100	Table	O
100	1	O
100	)	O
100	.	O
--------------------------------------------------------------
101	Seven	O
101	of	O
101	16	O
101	patients	O
101	(	O
101	43.8	O
101	percent	O
101	)	O
101	in	O
101	arm	B-arm_description
101	A	B-arm_description
101	were	O
101	intolerable	O
101	or	O
101	have	O
101	disease	O
101	-	O
101	progression	O
101	during	O
101	the	O
101	first	O
101	8-week	O
101	treatment	O
101	whereas	O
101	only	O
101	2	O
101	of	O
101	12	O
101	patients	O
101	(	O
101	16.7	O
101	percent	O
101	)	O
101	in	O
101	arm	B-arm_description
101	B	B-arm_description
101	were	O
101	withdrawn	O
101	from	O
101	the	O
101	study	O
101	earlier	O
101	.	O
101	Patients	O
101	had	O
101	higher	O
101	dropout	O
101	rate	O
101	(	O
101	43.8	O
101	percent	O
101	)	O
101	in	O
101	the	O
101	arm	O
101	A	O
101	because	O
101	of	O
101	higher	O
101	incidence	O
101	of	O
101	leucopenia	O
101	,	O
101	neutropenia	O
101	,	O
101	thrombocytopenia	O
101	,	O
101	and	O
101	patients	O
101	'	O
101	refusal	O
101	rate	O
101	in	O
101	regards	O
101	to	O
101	the	O
101	adverse	O
101	effects	O
101	of	O
101	interferon	O
101	alpha	O
101	.	O
--------------------------------------------------------------
102	Paraprotein	O
102	response	O
102	,	O
102	indicating	O
102	of	O
102	at	O
102	least	O
102	a	O
102	25	O
102	percent	O
102	decline	O
102	in	O
102	serum	O
102	or	O
102	urine	O
102	level	O
102	,	O
102	was	O
102	obtained	O
102	in	O
102	6	O
102	of	O
102	12	O
102	patients	O
102	(	O
102	50.0	O
102	percent	O
102	)	O
102	whom	O
102	were	O
102	treated	O
102	with	O
102	arm	B-arm_description
102	B	I-arm_description
102	,	O
102	and	O
102	3	O
102	of	O
102	the	O
102	16	O
102	patients	O
102	(	O
102	18.8	O
102	percent	O
102	)	O
102	whom	O
102	were	O
102	treated	O
102	with	O
102	arm	B-arm_description
102	A.	B-arm_description
102	Patients	O
102	in	O
102	arm	O
102	B	O
102	seems	O
102	to	O
102	have	O
102	higher	O
102	paraprotein	O
102	response	O
102	rate	O
102	(	O
102	PPR	O
102	)	O
102	in	O
102	our	O
102	study	O
102	.	O
102	There	O
102	were	O
102	2	O
102	paraprotein	O
102	responders	O
102	in	O
102	level	O
102	of	O
102	25	O
102	,	O
102	50	O
102	,	O
102	and	O
102	75	O
102	percent	O
102	reduction	O
102	of	O
102	serum	O
102	M	O
102	protein	O
102	in	O
102	arm	O
102	B	O
102	,	O
102	while	O
102	only	O
102	3	O
102	patients	O
102	in	O
102	arm	O
102	A	O
102	achieved	O
102	PPR	O
102	of	O
102	25	O
102	percent	O
102	.	O
102	Neither	O
102	a	O
102	PPR	O
102	≥90	O
102	percent	O
102	nor	O
102	complete	O
102	remissions	O
102	were	O
102	observed	O
102	in	O
102	this	O
102	study	O
102	.	O
102	Of	O
102	those	O
102	6	O
102	patients	O
102	who	O
102	had	O
102	response	O
102	to	O
102	thalidomide	O
102	alone	O
102	regimen	O
102	,	O
102	4	O
102	had	O
102	200	O
102	-	O
102	400	O
102	mg	O
102	of	O
102	thalidomide	O
102	per	O
102	day	O
102	and	O
102	the	O
102	other	O
102	2	O
102	patients	O
102	had	O
102	600	O
102	and	O
102	800	O
102	mg	O
102	per	O
102	day	O
102	,	O
102	respectively	O
102	.	O
102	In	O
102	patients	O
102	who	O
102	had	O
102	response	O
102	to	O
102	arm	O
102	A	O
102	regimen	O
102	,	O
102	2	O
102	patients	O
102	had	O
102	600	O
102	mg	O
102	and	O
102	one	O
102	had	O
102	400	O
102	mg	O
102	of	O
102	thalidomide	O
102	per	O
102	day	O
102	combined	O
102	with	O
102	IFN	O
102	-	O
102	α	O
102	during	O
102	their	O
102	treatment	O
102	periods	O
102	(	O
102	Table	O
102	2	O
102	)	O
102	.	O
--------------------------------------------------------------
103	The	O
103	median	O
103	time	O
103	to	O
103	response	O
103	were	O
103	42.0	O
103	days	O
103	(	O
103	95%CI	O
103	,	O
103	38.8∼45.2	O
103	)	O
103	and	O
103	69.0	O
103	days	O
103	(	O
103	95%CI	O
103	,	O
103	19.8∼118.2	O
103	)	O
103	in	O
103	arm	B-arm_description
103	A	B-arm_description
103	and	O
103	B	B-arm_description
103	,	B-arm_description
103	respectively	O
103	.	O
103	Median	O
103	duration	O
103	of	O
103	response	O
103	are	O
103	105.0	O
103	days	O
103	(	O
103	95%CI	O
103	,	O
103	64.9∼145.01	O
103	)	O
103	in	O
103	arm	O
103	A	O
103	and	O
103	357.0	O
103	days	O
103	(	O
103	95%CI	O
103	,	O
103	312.7∼401.3	O
103	)	O
103	in	O
103	arm	O
103	B.	O
103	Patients	O
103	who	O
103	received	O
103	thalidomide	B-arm_description
103	alone	I-arm_description
103	seems	O
103	to	O
103	have	O
103	longer	O
103	response	O
103	duration	O
103	than	O
103	thalidomide	B-arm_description
103	combined	I-arm_description
103	with	I-arm_description
103	IFN	I-arm_description
103	-	I-arm_description
103	α	I-arm_description
103	.	O
103	The	O
103	estimated	O
103	EFS	O
103	was	O
103	7.9	O
103	months	O
103	(	O
103	95%CI	O
103	,	O
103	0.5	O
103	-	O
103	15.4	O
103	)	O
103	and	O
103	1.5	O
103	months	O
103	(	O
103	95%CI	O
103	,	O
103	0.0	O
103	-	O
103	3.4	O
103	)	O
103	for	O
103	patients	O
103	receiving	O
103	arm	O
103	B	O
103	and	O
103	arm	O
103	A	O
103	,	O
103	respectively	O
103	(	O
103	log	O
103	-	O
103	rank	O
103	test	O
103	,	O
103	p	O
103	=	O
103	0.0193	O
103	)	O
103	.	O
103	There	O
103	was	O
103	no	O
103	statistically	O
103	significant	O
103	difference	O
103	of	O
103	overall	O
103	survival	O
103	between	O
103	arm	O
103	A	O
103	and	O
103	B	O
103	(	O
103	Figure	O
103	2	O
103	)	O
103	.	O
--------------------------------------------------------------
104	As	O
104	for	O
104	the	O
104	patients	O
104	in	O
104	arm	B-arm_description
104	B	B-arm_description
104	,	O
104	the	O
104	major	O
104	adverse	O
104	effects	O
104	were	O
104	neutropenia	O
104	(	O
104	50.0	O
104	percent	O
104	)	O
104	,	O
104	constipation	O
104	(	O
104	75.0	O
104	percent	O
104	)	O
104	,	O
104	and	O
104	edema	O
104	(	O
104	50.0	O
104	percent	O
104	,	O
104	face	O
104	or	O
104	extremities	O
104	)	O
104	.	O
104	Most	O
104	were	O
104	tolerable	O
104	after	O
104	dose	O
104	reductions	O
104	or	O
104	symptomatic	O
104	treatment	O
104	,	O
104	except	O
104	one	O
104	patient	O
104	with	O
104	severe	O
104	fluid	O
104	retention	O
104	on	O
104	his	O
104	face	O
104	and	O
104	extremities	O
104	and	O
104	skin	O
104	rashes	O
104	all	O
104	over	O
104	the	O
104	trunk	O
104	after	O
104	his	O
104	initial	O
104	12	O
104	days	O
104	of	O
104	treatment	O
104	and	O
104	was	O
104	withdrawn	O
104	from	O
104	the	O
104	study	O
104	.	O
104	In	O
104	5	O
104	patients	O
104	who	O
104	had	O
104	experienced	O
104	mild	O
104	to	O
104	moderate	O
104	edema	O
104	in	O
104	arm	O
104	B	O
104	,	O
104	the	O
104	average	O
104	treatment	O
104	-	O
104	duration	O
104	was	O
104	61.8	O
104	weeks	O
104	(	O
104	95%CI	O
104	,	O
104	39.7	O
104	-	O
104	83.9	O
104	)	O
104	.	O
104	Comparing	O
104	to	O
104	an	O
104	average	O
104	of	O
104	30.3	O
104	weeks	O
104	(	O
104	95%CI	O
104	,	O
104	10.8	O
104	-	O
104	49.8	O
104	)	O
104	for	O
104	the	O
104	other	O
104	6	O
104	patients	O
104	who	O
104	did	O
104	not	O
104	have	O
104	edema	O
104	during	O
104	the	O
104	study	O
104	,	O
104	it	O
104	suggested	O
104	that	O
104	the	O
104	longer	O
104	duration	O
104	of	O
104	thalidomide	O
104	used	O
104	,	O
104	the	O
104	higher	O
104	incidence	O
104	of	O
104	edema	O
104	developed	O
104	.	O
--------------------------------------------------------------
